EP1261322B1 - Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist - Google Patents
Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist Download PDFInfo
- Publication number
- EP1261322B1 EP1261322B1 EP00956773A EP00956773A EP1261322B1 EP 1261322 B1 EP1261322 B1 EP 1261322B1 EP 00956773 A EP00956773 A EP 00956773A EP 00956773 A EP00956773 A EP 00956773A EP 1261322 B1 EP1261322 B1 EP 1261322B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- active ingredient
- group
- use according
- adenosine
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 46
- 239000003379 purinergic P1 receptor agonist Substances 0.000 title abstract description 9
- 239000000296 purinergic P1 receptor antagonist Substances 0.000 title description 9
- 229940121359 adenosine receptor antagonist Drugs 0.000 title description 6
- 229940122614 Adenosine receptor agonist Drugs 0.000 title 1
- 230000000694 effects Effects 0.000 claims abstract description 80
- 229940079593 drug Drugs 0.000 claims abstract description 45
- 239000003814 drug Substances 0.000 claims abstract description 45
- 238000011282 treatment Methods 0.000 claims abstract description 39
- 201000002364 leukopenia Diseases 0.000 claims abstract description 35
- 231100001022 leukopenia Toxicity 0.000 claims abstract description 32
- 231100000331 toxic Toxicity 0.000 claims abstract description 25
- 230000002588 toxic effect Effects 0.000 claims abstract description 25
- 230000002265 prevention Effects 0.000 claims abstract description 21
- 230000010261 cell growth Effects 0.000 claims abstract description 20
- 238000004519 manufacturing process Methods 0.000 claims abstract description 19
- 230000002159 abnormal effect Effects 0.000 claims abstract description 18
- 239000004480 active ingredient Substances 0.000 claims description 99
- 210000004027 cell Anatomy 0.000 claims description 60
- IPSYPUKKXMNCNQ-PFHKOEEOSA-N (2s,3s,4r,5r)-5-[2-chloro-6-[(3-iodophenyl)methylamino]purin-9-yl]-3,4-dihydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NC)O[C@H]1N1C2=NC(Cl)=NC(NCC=3C=C(I)C=CC=3)=C2N=C1 IPSYPUKKXMNCNQ-PFHKOEEOSA-N 0.000 claims description 55
- 230000035755 proliferation Effects 0.000 claims description 51
- HUJXGQILHAUCCV-MOROJQBDSA-N 3-iodobenzyl-5'-N-methylcarboxamidoadenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C=C(I)C=CC=3)=C2N=C1 HUJXGQILHAUCCV-MOROJQBDSA-N 0.000 claims description 45
- 210000000265 leukocyte Anatomy 0.000 claims description 42
- 210000002798 bone marrow cell Anatomy 0.000 claims description 36
- 206010028980 Neoplasm Diseases 0.000 claims description 33
- 239000002246 antineoplastic agent Substances 0.000 claims description 32
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 30
- 230000037396 body weight Effects 0.000 claims description 30
- 229940044683 chemotherapy drug Drugs 0.000 claims description 29
- 102000005962 receptors Human genes 0.000 claims description 26
- 108020003175 receptors Proteins 0.000 claims description 26
- 238000002360 preparation method Methods 0.000 claims description 22
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 22
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 20
- 230000002401 inhibitory effect Effects 0.000 claims description 19
- 125000001188 haloalkyl group Chemical group 0.000 claims description 18
- 229910052739 hydrogen Inorganic materials 0.000 claims description 18
- 239000001257 hydrogen Substances 0.000 claims description 18
- -1 nitro, hydroxyl Chemical group 0.000 claims description 18
- 210000004881 tumor cell Anatomy 0.000 claims description 17
- 239000002593 adenosine A3 receptor agonist Substances 0.000 claims description 16
- 125000001475 halogen functional group Chemical group 0.000 claims description 15
- 150000002431 hydrogen Chemical class 0.000 claims description 15
- 229940122216 Adenosine A3 receptor agonist Drugs 0.000 claims description 14
- 150000001875 compounds Chemical class 0.000 claims description 14
- 230000001939 inductive effect Effects 0.000 claims description 14
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 claims description 12
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 12
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 12
- 229910052760 oxygen Inorganic materials 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 11
- 230000009977 dual effect Effects 0.000 claims description 10
- 150000003833 nucleoside derivatives Chemical group 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 229910052717 sulfur Inorganic materials 0.000 claims description 9
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 230000004069 differentiation Effects 0.000 claims description 8
- 230000004580 weight loss Effects 0.000 claims description 7
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 6
- 125000003282 alkyl amino group Chemical group 0.000 claims description 6
- 150000003931 anilides Chemical group 0.000 claims description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
- 125000000623 heterocyclic group Chemical group 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 6
- 239000001301 oxygen Substances 0.000 claims description 6
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 6
- 125000003107 substituted aryl group Chemical group 0.000 claims description 6
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 6
- 230000012010 growth Effects 0.000 claims description 5
- MWEQTWJABOLLOS-UHFFFAOYSA-L disodium;[[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-oxidophosphoryl] hydrogen phosphate;trihydrate Chemical compound O.O.O.[Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP([O-])(=O)OP(O)([O-])=O)C(O)C1O MWEQTWJABOLLOS-UHFFFAOYSA-L 0.000 claims description 4
- XTPOZVLRZZIEBW-SCFUHWHPSA-N (2r,3r,4s,5r)-2-[6-[2-(4-aminophenyl)ethylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical group C1=CC(N)=CC=C1CCNC1=NC=NC2=C1N=CN2[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 XTPOZVLRZZIEBW-SCFUHWHPSA-N 0.000 claims description 3
- LDYMCRRFCMRFKB-MOROJQBDSA-N (2s,3s,4r,5r)-5-[6-[(4-aminophenyl)methylamino]purin-9-yl]-3,4-dihydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C=CC(N)=CC=3)=C2N=C1 LDYMCRRFCMRFKB-MOROJQBDSA-N 0.000 claims description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims description 3
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims description 3
- 125000005865 C2-C10alkynyl group Chemical group 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 229910003813 NRa Inorganic materials 0.000 claims description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 3
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 3
- 150000005215 alkyl ethers Chemical class 0.000 claims description 3
- 125000004414 alkyl thio group Chemical group 0.000 claims description 3
- 125000003368 amide group Chemical group 0.000 claims description 3
- 230000000259 anti-tumor effect Effects 0.000 claims description 3
- 208000008784 apnea Diseases 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 3
- 125000002648 azanetriyl group Chemical group *N(*)* 0.000 claims description 3
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- 125000004181 carboxyalkyl group Chemical group 0.000 claims description 3
- 125000004966 cyanoalkyl group Chemical group 0.000 claims description 3
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 claims description 3
- 230000003028 elevating effect Effects 0.000 claims description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000005030 pyridylthio group Chemical group N1=C(C=CC=C1)S* 0.000 claims description 3
- 239000011593 sulfur Chemical group 0.000 claims description 3
- 150000007970 thio esters Chemical class 0.000 claims description 3
- 125000005309 thioalkoxy group Chemical group 0.000 claims description 3
- 150000003568 thioethers Chemical class 0.000 claims description 3
- 238000011394 anticancer treatment Methods 0.000 claims description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 abstract description 31
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 abstract description 31
- 230000005764 inhibitory process Effects 0.000 abstract description 13
- 230000004663 cell proliferation Effects 0.000 abstract description 12
- 230000028327 secretion Effects 0.000 abstract description 12
- 239000000556 agonist Substances 0.000 abstract description 10
- 101150046889 ADORA3 gene Proteins 0.000 abstract description 5
- 230000006698 induction Effects 0.000 abstract description 5
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 92
- 241000699670 Mus sp. Species 0.000 description 54
- 229960005305 adenosine Drugs 0.000 description 46
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 45
- 238000002474 experimental method Methods 0.000 description 24
- 210000000440 neutrophil Anatomy 0.000 description 18
- 238000002512 chemotherapy Methods 0.000 description 17
- 238000000034 method Methods 0.000 description 16
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 14
- 238000003556 assay Methods 0.000 description 14
- 230000001225 therapeutic effect Effects 0.000 description 14
- FFBDFADSZUINTG-UHFFFAOYSA-N DPCPX Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C1CCCC1 FFBDFADSZUINTG-UHFFFAOYSA-N 0.000 description 12
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 12
- 206010025323 Lymphomas Diseases 0.000 description 12
- 239000000670 adrenergic alpha-2 receptor antagonist Substances 0.000 description 11
- 238000010348 incorporation Methods 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 230000009467 reduction Effects 0.000 description 10
- TWWFAXQOKNBUCR-UHFFFAOYSA-N N-[9-chloro-2-(2-furanyl)-[1,2,4]triazolo[1,5-c]quinazolin-5-yl]-2-phenylacetamide Chemical compound N12N=C(C=3OC=CC=3)N=C2C2=CC(Cl)=CC=C2N=C1NC(=O)CC1=CC=CC=C1 TWWFAXQOKNBUCR-UHFFFAOYSA-N 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 238000007912 intraperitoneal administration Methods 0.000 description 9
- 230000004614 tumor growth Effects 0.000 description 9
- 208000001382 Experimental Melanoma Diseases 0.000 description 8
- 229940127089 cytotoxic agent Drugs 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 206010009944 Colon cancer Diseases 0.000 description 7
- 241000699660 Mus musculus Species 0.000 description 7
- 239000005557 antagonist Substances 0.000 description 7
- 210000001185 bone marrow Anatomy 0.000 description 7
- 239000002254 cytotoxic agent Substances 0.000 description 7
- 239000012091 fetal bovine serum Substances 0.000 description 7
- 230000007085 granulocyte colony-stimulating factor production Effects 0.000 description 7
- 238000011580 nude mouse model Methods 0.000 description 7
- 230000000638 stimulation Effects 0.000 description 7
- 241000282414 Homo sapiens Species 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 239000012979 RPMI medium Substances 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 229960004679 doxorubicin Drugs 0.000 description 6
- 238000011081 inoculation Methods 0.000 description 6
- 208000004235 neutropenia Diseases 0.000 description 6
- UUSHFEVEROROSP-UHFFFAOYSA-N propyl 6-ethyl-5-ethylsulfanylcarbonyl-2-phenyl-4-propylpyridine-3-carboxylate Chemical compound CCCOC(=O)C1=C(CCC)C(C(=O)SCC)=C(CC)N=C1C1=CC=CC=C1 UUSHFEVEROROSP-UHFFFAOYSA-N 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 229960004397 cyclophosphamide Drugs 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000013543 active substance Substances 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 102000030621 adenylate cyclase Human genes 0.000 description 4
- 108060000200 adenylate cyclase Proteins 0.000 description 4
- 238000004820 blood count Methods 0.000 description 4
- 230000000973 chemotherapeutic effect Effects 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- SQMWSBKSHWARHU-SDBHATRESA-N n6-cyclopentyladenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(NC3CCCC3)=C2N=C1 SQMWSBKSHWARHU-SDBHATRESA-N 0.000 description 4
- 239000002777 nucleoside Substances 0.000 description 4
- 230000004565 tumor cell growth Effects 0.000 description 4
- BUHVIAUBTBOHAG-FOYDDCNASA-N (2r,3r,4s,5r)-2-[6-[[2-(3,5-dimethoxyphenyl)-2-(2-methylphenyl)ethyl]amino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound COC1=CC(OC)=CC(C(CNC=2C=3N=CN(C=3N=CN=2)[C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)C=2C(=CC=CC=2)C)=C1 BUHVIAUBTBOHAG-FOYDDCNASA-N 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 3
- 102000009346 Adenosine receptors Human genes 0.000 description 3
- 108050000203 Adenosine receptors Proteins 0.000 description 3
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 238000012404 In vitro experiment Methods 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000001767 chemoprotection Effects 0.000 description 3
- 229940124444 chemoprotective agent Drugs 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000000099 in vitro assay Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000000689 upper leg Anatomy 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 0 *[C@](C([C@@]1O)OC=C)OC1I(C=*1)C2=C1C(C(C#I=C)P)=*C([Np])=C=C2 Chemical compound *[C@](C([C@@]1O)OC=C)OC1I(C=*1)C2=C1C(C(C#I=C)P)=*C([Np])=C=C2 0.000 description 2
- 101150007969 ADORA1 gene Proteins 0.000 description 2
- 229940119226 Adenosine A2 receptor agonist Drugs 0.000 description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000002582 adenosine A1 receptor agonist Substances 0.000 description 2
- 239000002597 adenosine A2 receptor agonist Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 230000009699 differential effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000005714 functional activity Effects 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 230000017066 negative regulation of growth Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002633 protecting effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- IGFXRKMLLMBKSA-UHFFFAOYSA-N purine Chemical compound N1=C[N]C2=NC=NC2=C1 IGFXRKMLLMBKSA-UHFFFAOYSA-N 0.000 description 2
- 229940044601 receptor agonist Drugs 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- HUJXGQILHAUCCV-FEWYLQRLSA-N (2S,3R,5R)-3,4-dihydroxy-5-[6-[(3-iodophenyl)methylamino]-9-purinyl]-N-methyl-2-oxolanecarboxamide Chemical compound OC1[C@@H](O)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C=C(I)C=CC=3)=C2N=C1 HUJXGQILHAUCCV-FEWYLQRLSA-N 0.000 description 1
- XSMYYYQVWPZWIZ-IDTAVKCVSA-N (2r,3r,4s,5r)-2-[2-chloro-6-(cyclopentylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC(Cl)=NC(NC3CCCC3)=C2N=C1 XSMYYYQVWPZWIZ-IDTAVKCVSA-N 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- ORAQXGJNNYRIAI-UHFFFAOYSA-N 6-ethyl-5-ethylsulfanylcarbonyl-2-phenyl-3,4-dipropyl-4H-pyridine-3-carboxylic acid Chemical compound CCCC1C(=C(N=C(C1(CCC)C(=O)O)C2=CC=CC=C2)CC)C(=O)SCC ORAQXGJNNYRIAI-UHFFFAOYSA-N 0.000 description 1
- 108010060263 Adenosine A1 Receptor Proteins 0.000 description 1
- 102000030814 Adenosine A1 receptor Human genes 0.000 description 1
- 229940124049 Adenosine A2 receptor antagonist Drugs 0.000 description 1
- 108010060261 Adenosine A3 Receptor Proteins 0.000 description 1
- 102000008161 Adenosine A3 Receptor Human genes 0.000 description 1
- 229940123786 Adenosine A3 receptor antagonist Drugs 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 244000205754 Colocasia esculenta Species 0.000 description 1
- 235000006481 Colocasia esculenta Nutrition 0.000 description 1
- 208000027205 Congenital disease Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 230000006370 G0 arrest Effects 0.000 description 1
- 230000037057 G1 phase arrest Effects 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 108091006101 Gi proteins Proteins 0.000 description 1
- 102000034354 Gi proteins Human genes 0.000 description 1
- 108091006065 Gs proteins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000003449 adenosine A2 receptor antagonist Substances 0.000 description 1
- 239000002580 adenosine A3 receptor antagonist Substances 0.000 description 1
- 150000003835 adenosine derivatives Chemical class 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003200 antithyroid agent Substances 0.000 description 1
- 229940043671 antithyroid preparations Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 150000008107 benzenesulfonic acids Chemical class 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000009073 conformational modification Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000002435 cytoreductive effect Effects 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000000044 effect on lymphoma Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 201000004108 hypersplenism Diseases 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000002556 myelotoxic effect Effects 0.000 description 1
- MRWXACSTFXYYMV-FDDDBJFASA-N nebularine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC=C2N=C1 MRWXACSTFXYYMV-FDDDBJFASA-N 0.000 description 1
- 230000003957 neurotransmitter release Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 125000001484 phenothiazinyl group Chemical class C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 239000013630 prepared media Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002212 purine nucleoside Substances 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 201000009225 splenic sequestration Diseases 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000006442 vascular tone Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention is generally in the field of cancer and concerns a cancer therapy or a therapy intended to counter the side effect of cancer treatment.
- Myelotoxicity is a prevailing, severe, complication of chemotherapy and is one of the factors that limit the administrable dose of the chemotherapeutic drug. It causes more life threatening patient morbidity and actual mortality than any other chemotherapeutic side effect and may result in an increased number of hospital stay days. In addition, drug induced myelosuppression limits the administration of larger, potentially more effective doses of chemotherapy to patients with malignancies.
- GM-CSF granulocyte-macrophage colony stimulating factor
- G-CSF granulocyte-colony stimulating factor
- G-CSF growth factor
- Adenosine an endogenous purine nucleoside
- Adenosine present in the plasma and other extracellular fluids mediates many of its physiological effects via cell surface receptors and is an important regulatory protein. It is released into the extracellular environment from metabolically active or stressed cells. It is known to act through its binding to specific G-protein associated A1, A2 and A3 membranal receptors (1-2) .
- G-protein associated A1, A2 and A3 membranal receptors 1-2
- the interaction of adenosine with its receptors initiates signal transduction pathways, mainly the adenylate cyclase effector system, which utilizes cAMP as a second messenger.
- A1 and A3 receptors which are coupled with Gi proteins, inhibit adenylate cyclase and lead to a decrease in the level of intracellular cAMP
- the A2 receptor which is coupled to Gs proteins, activates adenylate cyclase, thereby increasing cAMP levels (3) .
- Adenosine exerts various effects on the immune system including anti-inflammatory activity through the inhibition of cytokine release, inhibition of platelet aggregation, induction of erythropoietin production and modulation of the lymphocyte function (8-10) . Further, adenosine was found to play a role in the modulation of some central nervous system (CNS) functions, in wound healing, in diuresis and in controlling pain. It was also demonstrated that adenosine is capable of inducing proliferation in a wide range of normal cell types( 11-14 ) . This modulation of cell growth is likely mediated through the adenylate cyclase effector system described above.
- adenosine acts as a chemoprotective agent, which activity is likely related to its capability to stimulate bone marrow cell proliferation. Further, it was found that adenosine exerted an inhibitory effect on the proliferation of tumor cells, apparently through G0/G1 cell cycle arrest and reduction of the telomeric signal (17-18) . The dual effect has turned adenosine into an attractive concept for cancer treatment.
- A3RAg adenosine A3 receptor agonists
- A3RAg compounds inhibit proliferation and growth of tumor cells, synergize with an anti-tumor cytotoxic drug in reducing the tumor load, induce proliferation and differentiation of bone marrow cells and white blood cells and counter toxic side effects of other drugs, particularly chemotherapeutic drugs.
- the A3RAg exerts these activities by a variety of forms of administration including parenteral administration and particularly oral administration.
- A3RAg activity may be mimicked by other agonists and antagonists of the adenosine A1 or A2 receptors: the adenosine A1 receptor agonists (A1RAg) shares with the A3RAg its ability to induce G-CSF secretion; adenosine A2 receptor agonist (A2RAg) shares with the A3R.A,g its ability to inhibit proliferation of malignant cells; and the adenosine A2 receptor antagonist (A2RAn) shares with the A3RAg its ability to counter toxic side effects of drugs, e.g. treat or prevent leukopenia.
- A1RAg adenosine A1 receptor agonists
- A2RAg adenosine A2 receptor agonist
- A2RAn adenosine A2 receptor antagonist
- the invention relates in its broadest sense, to the use of an active ingredient to yield one of the following therapeutic/biological effects: inducing production or secretion of G-CSF within the body; prevention or treatment of toxic side effects of a drug or prevention or treatment of leukopenia, particularly drug-induced leukopenia; and inhibition of abnormal cell growth and proliferation.
- the active ingredient may be an A3RAg or an agonist or antagonist of the adenosine receptor system which can yield one of these therapeutic effects, achieved by the use of the A3RAg.
- the first embodiment to be referred to herein as the "G-CSF-inducing embodiment" involves the use of an active ingredient, which may be an A3Rag to yield secretion of the G-CSF within the body of a treated subject.
- G-CSF is known to stimulate proliferation and differentiation of hematopoietic progenitors and controls the functional activities of neutrophils and macrophages.
- a G-CSF-inducing agent such as those mentioned above, may have a high therapeutic value, for example, in countering (i.e. preventing, reducing or ameliorating) myelotoxicity.
- a method for inducing G-CSF secretion within the body of a subject comprising administering to the subject an effective amount of an active ingredient A3RAg.
- a method for the therapeutic treatment comprising administering to a subject in need an effective amount of said active ingredient for achieving a therapeutic effect, the therapeutic effect comprises induction of G-CSF production or secretion.
- use of said active ingredient for the manufacture of a pharmaceutical composition for inducing G-CSF secretion.
- a pharmaceutical composition for inducing production or secretion of G-CSF within the body comprising a pharmaceutically acceptable carried an effective amount of said active ingredient.
- an active ingredient which may be an A3RAg, is used for the prevention or treatment of leukopenia, which may result from myelotoxicity.
- a method for inducing proliferation or differentiation of bone marrow or white blood cells in a subject comprising administering to the subject an effective amount of an active ingredient A3RAg.
- a method for prevention or treatment of leukopenia comprising administering to a subject in need an effective amount of said active ingredient.
- use of said active ingredient for the manufacture of a pharmaceutical composition for inducing proliferation or differentiation of bone marrow or white blood cells is use of said active ingredient for the manufacture of a pharmaceutical composition for the prevention or treatment of leukopenia.
- the pharmaceutical composition can particularly be used for prevention or treatment of leukopenia.
- the abovementioned active ingredient namely A3RAg
- the abovementioned active ingredient is used to counter toxic side effects of drugs, such as chemotherapeutic drugs or nemoleptic drugs.
- a method for prevention or treatment of toxic side effects of a drug comprising administering to a subject in need an effective amount of an active ingredient A3RAg.
- use of said active ingredient for the manufacture of a pharmaceutical composition for the prevention or treatment of drug-induced toxicity.
- pharmaceutical composition for prevention or treatment of toxic side effects of a drug comprising an effective amount of said active ingredient and a pharmaceutically acceptable carrier.
- the invention thus also provides a pharmaceutical composition
- a pharmaceutical composition comprising, in combination a drug that can cause toxic side effect in a subject treated thereby and said active ingredient; as well as use of said active ingredient for the manufacture of such a pharmaceutical composition.
- Said active ingredients included in said composition being an amount effective for prevention or treatment of the toxic side effects.
- an active ingredient which may be an A3RAg, is used for selectively inhibiting abnormal cell growth, e.g. tumor cell growth.
- a method for inhibiting abnormal cell growth in a subject comprising administering to the subject a therapeutically effective amount of an active ingredient A3RAg. Also provided in accordance with this embodiment is use of said active ingredient for the manufacture of a pharmaceutical composition for inhibiting abnormal cell growth. Still further provided by this embodiment is a pharmaceutical composition for inhibiting abnormal cell growth, comprising said active ingredient, and a pharmaceutically acceptable carrier.
- the administration of the active ingredient is intended to achieve dual therapeutic effect: inhibition of abnormal cell growth and reduction of toxic side effects of a drug causing such effects.
- the preferred active ingredient in accordance with the invention is an A3RAg.
- the preferred route of administration of the active ingredient, in accordance with the invention is the oral administration route. However, this preference does not exclude other active ingredients neither other administration routes of the active ingredients.
- the dosage of the active ingredient is preferably less than 100 ⁇ g/kg body weight, typically less than 50 ⁇ g and desirably within the range of 1-10 ⁇ g/kg body weight.
- the invention relates to the use of an effective amount of an active ingredient for the preparation of a pharmaceutical composition for countering drug-induced myelotoxicity, wherein said active ingredient is an adenosine A3 receptor agonist (A3RAg), which exerts its prime effect through the A3 receptor and has the following general formula (I): wherein R 1 is C 1 -C 10 alkyl, C 1 -C 10 hydroxyalkyl, C 1 -C 10 carboxyalkyl or C 1 -C 10 cyanoalkyl or a group of the following general formula (II): in which:
- the active ingredient is a nucleoside derivative of the general formula (IV): wherein X 1 , R 2 and R 5 are as defined above.
- the active ingredient is an N 6 -benzyladenosine-5'-uronamide derivative.
- the active ingredient is selected from N 6 -2-(4-aminophenyl)ethyladenosine (APNEA), N 6 -(4-amino-3-iodobenzyl) adenosine-5'-(N-methyluronamide) (AB-MECA), N 6 -(3-iodobenzyl)-adenosine-5'-N-methyl-uronamide (IB-MECA) and 2-chloro-N 6 -(3-iodobenzyl)-adenosine- 5'-N-methyl-uronamide (CI-IB-MECA).
- APIA N 6 -2-(4-aminophenyl)ethyladenosine
- AB-MECA N 6 -(4-amino-3-iodobenzyl) adenosine-5'-(N-methyluronamide)
- IB-MECA N 6 -(3-iodobenzyl)-
- the active ingredient is N 6 -benzyl- adenosine-5'-alkyluronamide-N 1 -oxide or N 6 -benzyladenosine-5'-N-dialyl-uron- amide-N 1 oxide.
- the active ingredient is a xanthine-7-riboside derivative of the following general formula (V):- wherein:
- the drug is a chemotherapeutic drug given to the subject within the framework of anti-cancer treatment.
- the present invention also relates to the use of an effective amount of an active ingredient for the preparation of a pharmaceutical composition for inducing proliferation or differentiation of bone marrow or white blood cells, wherein the active ingredient is an adenosine A3 receptor agonist (A3RAg), which exerts its prime effect through the A3 receptor and is as defined above.
- A3RAg adenosine A3 receptor agonist
- the present invention further relates to the use of an effective amount of an active ingredient for the preparation of a pharmaceutical composition for the prevention or treatment of leukopenia, the active ingredient being an adenosine A3 receptor agonist (A3RAg), which exerts its prime effect through the A3 receptor and is as defined above.
- A3RAg adenosine A3 receptor agonist
- the leukopenia is drug- induced leukopenia.
- the present invention relates to the use of an effective amount of an active ingredient for the preparation of a pharmaceutical composition for the prevention or treatment of toxic side effects of a drug, the active ingredient being an adenosine A3 receptor agonist (A3RAg), which exerts its prime effect through the A3 receptor and is as defined above.
- A3RAg adenosine A3 receptor agonist
- the toxic side effect is manifested by weight loss.
- the drug is a chemotherapeutic drug.
- the pharmaceutical composition is for elevating the level of circulating leukocytes in a subject.
- the present invention also relates to the use of an effective amount of an active ingredient being an adenosine A3 receptor agonist (A3RAg), which exerts its prime effect through the A3 receptor, for the manufacture of a pharmaceutical composition, wherein said manufacture comprises mixing said active ingredient with a drug that can cause a toxic side effect in a treated subject.
- A3RAg adenosine A3 receptor agonist
- the drug is a chemotherapeutic drug.
- the present invention also relates to the use of an effective amount of an active ingredient for the preparation of a pharmaceutical composition for selectively inhibiting abnormal cell growth, the active ingredient being an adenosine A3 receptor agonist (A3RAg), which exerts its prime effect through the A3 receptor and is as defined above.
- A3RAg adenosine A3 receptor agonist
- the abnormal cell growth is the growth or proliferation of tumor cells.
- the abnormal cell-growth is associated with an autoimmune disease.
- the pharmaceutical composition is intended for administration in combination with a chemotherapeutic drug.
- the present invention further relates to the use of an effective amount of an A3RAg, which exerts its prime effect through the A3 receptor, for the preparation of a pharmaceutical composition for the treatment of cancer in a subject, the pharmaceutical composition yielding a dual effect in both inhibiting proliferation of cancer cells and countering toxic side effects of a chemotherapeutic drug treatment of the same subject, wherein the active ingredient is as defined above.
- the active ingredient synergizes with said drug to yield a stronger anti-tumor effect
- the active ingredient is formulated for oral administration.
- the dosage of the A3RAg is ⁇ 100 ⁇ g/kg body weight, preferably ⁇ 50 ⁇ g/kg body weight, more preferably within the range of 1-10 ⁇ g/kg body weight.
- the G-CSF-inducing embodiment some such agents are used to mediate the production and secretion of G-CSF from cells.
- the toxicity-preventing embodiment some such agents are used to counter toxic side effects of drugs, e.g. chemotherapeutic or nemoleptic drugs.
- the leukopenia-prevention embodiment some such agents are used to counter leukopenia, particularly drug induced leukopenia.
- the proliferation-inhibition embodiment some such agents are used to selectively inhibit abnormal cell growth.
- leukopenia refers to the reduction in the circulating white blood cell count. While leukopenia is usually characterized by a reduced number of blood neutrophils (neutropenia), at times, a reduced number of lymphocytes, monocytes, eosinophils or basophils may be detected.
- Leukopenia which may arise from the reduced production or excessive splenic sequestration of neutrophils, may result from a hereditary and congenital diseases. However it is mainly observed after treatment with drugs, such as cytoreductive cancer drugs, antithyroid drugs, phenothiazines, anticonvulsants, penicillins, sulfonamides, and chloramphenicol. Some antineoplastics cause leukopenia as a predictable side effect.
- prevention or treatment of leukopenia should be understood as a procedure whereby the reduction in leukocyte cell count which may otherwise occur, is reduced, totally prevented or if such reduction has occurred, a procedure which gives rise to increase in the leukocyte cell count.
- Leukopenia is manifested by a variety of side effects such as an increased possibility to infection by significant infectious agents and others.
- prevention or treatment of leukopenia should also be understood as meaning an improvement in such parameters which may occur as a result of leukopenia.
- the pharmaceutically or therapeutically "effective amount" for purposes herein is determined by such considerations as may be known in the art.
- the amount must be effective to achieve the desired therapeutic effect which depends on the type and mode of treatment. As is clear to the artisan, the amount should be effective to obtain the improvement of survival rate, to obtain a more rapid recovery, to obtain the improvement or elimination of symptoms or any other indicators as are selected as appropriate measures by those skilled in the art.
- an effective amount of the active ingredient may be an amount which leads to production and secretion of G-CSF from peripheral blood mononuclear cells, endothelial cell or fibroblast, in which it was produced, thereby, for example, stimulating the maturation of granulocytes progenitors into mature neutrophils.
- an effective amount of the active ingredient may be an amount which protects the individual against the drug-induced reduction in the count of leukocytes, particularly neutrophils; an amount of the active ingredient which can give rise to an increase in an already decreased level of such cells, e.g. restore the level to a normal level or sometimes even above; etc.
- the amount of the active ingredient may, for example, be an amount effective in reduction of weight loss resulting from the drug administered.
- an effective amount may be an amount which will inhibit the proliferation of such cells in the treated subject and even eliminate the tumor.
- an effective amount may be an amount which either increases the cancer specific toxicity of the chemotherapeutic treatment; an amount which is effective in reducing the amount of the chemotherapeutic drug or drug combination required to achieve a desired effect of the chemotherapeutic drug or drug combination, i.e.
- An example of an effective amount is a daily administration of A3RAg less than 100 ⁇ g/kg body weight, typically less than 50 ⁇ g/kg body weight and optionally even less than 10 ⁇ g/kg body weight, e.g. about 3-6 ⁇ g/kg body weight.
- Such an amount of A3RAg is typically administered in a single-daily dose although at times a daily dose may be divided into several doses administered throughout the day or at times several daily doses may be combined into a single dose to be given to the patient once every several days, particularly if administered in a sustained release formulation.
- the active ingredient according to the invention is an A3RAg.
- the A3RAg is any agonist which binds to A3 receptors and activates them to yield a therapeutic effect of the present invention. It should be noted that at times, an A3RAg may also interact with other receptors, e.g. with the A 1 and A2 receptors. However, the A3RAg used in accordance with the invention exerts its prime effect through the A3 receptor (namely there may also be minor effects exerted through interaction with other adenosine receptors).
- the active ingredient according to the invention is a nucleoside derivative.
- nucleoside it is meant any compound comprising a sugar, preferably ribose or deoxyribose, or a purine or pyrimidine base or a combination of a sugar with a purine or pyrimidine base preferably by way of N-glycosyl link.
- nucleoside derivative will be used to denote herein a naturally occurring nucleoside as define hereinabove, a synthetic nucleoside or a nucleoside which underwent chemical modifications by way of insertion/s, deletion/s or exocyclic and endocyclic substitution/s of group/s therein or conformational modifications which provide a derivative with the desired biological effect.
- the active ingredient is an A3RAg.
- the active ingredient is a nucleoside derivative of the following general formula (I): wherein R 1 is C 1 -C 10 alkyl, C 1 -C 10 hydroxyalkyl, C 1 -C 10 carboxyalkyl or C 1 -C 10 cyanoalkyl or a group of the following general formula (II): in which:
- the active ingredient is preferably a nucleoside derivative of the general formula (IV): wherein X 1 R 2 and R 4 are as defined above and
- N6-benzyladenosine-5'-uronamides and derivatives thereof found to be A3-selective adenosine receptor agonists.
- Examples for such derivatives arc N 6 -2-(4-aminophenyl)ethyladenosine (APNEA), N 6 -(4-amino-3-iodobenzyl) adenosine-5'-(N-methyluronamide) (AB-MECA) and 1-deoxy-1- ⁇ 6-[( ⁇ 3-iodophenyl ⁇ methyl)amino]- 9H-purine-9-yl ⁇ -N-methyl- ⁇ -D-ribofuranuron-amide the latter also referred to in the art as N 6 -3-idobenzyl -5'-methylcarboxamidoadenosine, N6-(3-idobenzyl) adenosine-5'-N-methyl
- the active ingredient may be adenosine derivative generally referred to as N 6 -benzyl-adenosine-5'-alkyluronamide-N'-oxide or N 6 -benzyladenosine-5'-N- dialyluron-amide -N 1 -oxide.
- the active ingredient may be a xanthine-7-riboside derivative of the following general formula (V): wherein:
- the active ingredient in accordance with the invention may be as defined above or may be in the form of salts or solvates thereof, in particular physiologically acceptable salts and solvates thereof Further, when containing one or more asymmetric carbon atoms, the active ingredient may include isomers and diastereoisomers of the above active ingredients or mixtures thereof.
- Pharmaceutically acceptable salts of the above active ingredients include those derived from pharmaceutically acceptable inorganic and organic acids.
- suitable acids include hydrochloric, hydrobromic, sulphoric, nitric, perchloric, fumaric, maleic, phosphoric, glycollic, lactic, salicylic, succinic, toluene-p-sulfonic, tartaric, acetic, citric, methanesulfonic, formic, benzoic, malonic, naphthalene-2-sulfonic and benzenesulfonic acids.
- the active ingredient may be administered as a non-active substance (e.g. pro-drug) and be made active only upon further modification/s by a natural process at a specific site in the subject.
- the derivative will be such that the therapeutic functionality of the pharmaceutical composition of the invention, is preserved.
- pro-drugs are also encompassed by the term “active ingredient” as used herein.
- the terms “A3RAg”, “A1RAg'' “ ⁇ 1RAn” "A2RAg” and “A2RAn should be understood as encompassing pro-drugs which, although a priori, lack the agonistic or antagonistic activity (as the case may be), become active in vivo .
- the A3RAg in accordance with the invention may be chosen by screening for such compounds which qualitatively have an activity resembling that of IB-MECA.
- such compounds for use in accordance with the leukopenia-inhibiting embodiment may be screened based on their ability to stimulate proliferation of bone marrow or white blood cells and subsequently based on their ability to exert this activity in vivo.
- compounds for use in the proliferation-inhibition embodiment may be screened for their ability to inhibit proliferation of tumor cells as well as subsequently to exert this activity in vivo.
- the A1RAn and A2RAn may be tested for their activity and screened for use in therapy in a similar manner, mutatis mutandis, to that described for A3RAg.
- the pharmaceutical composition of the invention may comprise the active ingredient as such, but may be combined with other ingredients which may be a pharmaceutically acceptable carrier, diluent, excipient, additive and/or adjuvent, as known to the artisan, e.g. for the purposes of adding flavors, colors, lubrication or the like to the pharmaceutical composition.
- a pharmaceutically acceptable carrier/s, diluent/s, excipient/s, additive/s employed according to the invention generally refer to inert, non-toxic solid or liquid fillers, diluents or encapsulating materials which preferably do not react with the compounds within the composition of the invention.
- the active ingredient may also be administered in combination with a chemotherapeutic drug, particularly in the case of the leukopenia prevention embodiment.
- the pharmaceutical composition according to the invention may comprise, in addition to said active ingredient a chemotherapeutic drug.
- the chemotherapeutic drug is an anti-cancer chemotherapeutic drug. It should be understood that by the term it is meant any cytotoxic drug or a cocktail comprising a combination of two or more cytotoxic drugs given to a patient for the purpose of reducing the patient's tumor mass.
- the pharmaceutical composition of the invention is formulated for oral administration.
- Such an oral composition may further comprise a pharmaceutically acceptable carrier, diluent, excipient, additive or adjuvant suitable for oral administration.
- the pharmaceutical compositions disclosed are particularly used for increasing the level of G-CSF secreted from the cells.
- Such compositions may be used to accelerate the neutrophil recovery after chemotherapy and bone marrow transplantation or to inhibit abnormal cell growth.
- treatments include administration of the growth factor it self, which are known to have undesired side effects. All the more so, the average cost per course of G-CSF therapy is known to be very high.
- the pharmaceutical composition disclosed are particularly used for elevating the level of circulating leukocyte cells in a subject or countering other toxic effects, such as weight loss.
- This aspect of the invention is applicable in a variety of clinical situations. It is evident that a reduced level of circulating leukocytes and particularly neutrophils may result in a weakened immune system.
- An example of a weakened immune system which may be treated in accordance with this aspect of the invention, is such which often occurs in advanced stages of cancer or that resulting from drug-induced leukopenia or drug-induced neutropenia.
- the proliferation-inhibiting embodiment is useful for the treatment of a variety of abnormalities associated with the abnormal cell growth such as cancer, psoriasis and some autoimmune diseases.
- the composition of the invention is employed for inhibiting proliferation of tumor cells, preferably within the framework of anti-cancer therapy.
- A3RAgs were further found to be potent in inhibiting growth of tumor cells, other than lymphoma, e.g. melanoma or colon carcinoma (see for example Fig. 6).
- lymphoma e.g. melanoma or colon carcinoma
- a man versed in the art would clearly appreciate the advantage of treating a subject with a non-specific anti-cancer drug capable of inhibiting growth of the abnormally dividing cells while concomitantly being capable restoring the immune system of the subject by inducing bone marrow cell proliferation.
- Figs. 7A-7B show the differential effect of A3RAg.
- the effect of IB-MECA on tumor and normal cells was evaluated.
- the therapeutic effect of A3RAg was reversed when an A3 receptor antagonist, MRS-1220, was employed.
- Figures 10A-10B as well as 19A and 19B show that tumor-bearing mice treated only with the cytotoxic drug exhibited a decline in the number of peripheral blood leukocytes and neutrophils, while administration of A3RAg after chemotherapy, resulted in the restoration of the total white blood cell count yielding an increase in the percentage of neutrophils.
- A3RAg has a dual therapeutic function as it acts both as a chemotherapeutic agent as well as a chemoprotective agent. It is clear that use of A3RAg for this dual effect is also within the scope of the present invention.
- compositions of the invention are administered and dosed in accordance with good medical practice, taking into account the clinical condition of the individual patient, the site and method of administration, scheduling of administration, patient's age, sex, body weight and other factors known to medical practitioners.
- composition of the invention may be administered in various ways. It can be administered orally, subcutaneously or parenterally including intravenous, intraarterial, intramuscular, intraperitoneally or by intranasal administration, as well as by intrathecal and infusion techniques known to the man versed in the art.
- a treatment course in humans is usually longer than in animals, e.g. mice, as exemplified herein.
- the treatment has a length proportional to the length of the disease process and active agent effectiveness.
- the therapeutic regimen involved single doses or multiple doses over a period of several days or more.
- the treatment generally has a length contingent with the course of the disease process, active agent effectiveness and the patient species being treated.
- compositions of the present invention When administering the compositions of the present invention parenterally, it will generally be formulated in a unit dosage injectable form (solution, suspension, emulsion).
- the pharmaceutical formulation suitable for injection includes sterile aqueous solutions or dispersions and sterile powders for reconstitution into sterile injectable solutions or dispersions.
- the carrier employed can be a solvent or dispersing medium containing, for example, water, ethanol, polyol (tor example, glycerol, propylene glycol, lipid polyethylene glycol and the like), suitable mixtures thereof and vegetable oils.
- Non-aqueous vehicles such as cottonseed oil, sesame oil, olive oil, soybean oil, corn oil, sunflower oil, or peanut oil and ester, such as isopropyl myristate, may also at times be used as solvent systems for the active ingredient.
- compositions which enhance the stability, sterility and isotonicity of the compositions, including antimicrobial preservatives, antioxidants, chelating agents and buffers can be added.
- antimicrobial preservatives including antimicrobial preservatives, antioxidants, chelating agents and buffers
- buffers can be added.
- antibacterial and antifungal agents for example, parabens, chlorobutanol, phenol, sorbic acid and the like.
- the active ingredient may be formulated in the form of tablets, suspensions, solutions, emulsions, capsules, powders, syrups and the like, are usable and may be obtained by techniques well known to the pharmacists.
- Murine tumor cell lines (B-16 melanoma and Nb2 11c rat Lymphoma) were used.
- B-16 melanoma cells were obtained from the American Type Tissue Culture Collection (ATCC), Rockville, Maryland.
- Nb2-11C rat lymphoma cells [ Pines M., and Gertler A. J. of Cellular Biochem., 37:119-129 (1988 )] was kindly provided by Dr. A. Gertler, Hebrew university, Israel.
- Colon carcinoma cells (HCT-116) were also employed and were obtained at the ATCC.
- the cells were routinely maintained in RPMI medium containing 10% fetal bovine serum (FBS, Biological Industries, Beit Haemek, Israel). Twice a week the cells were transferred to a freshly prepared medium.
- FBS fetal bovine serum
- Bone marrow cells derived from the femur of C57BL/6J mice were used. The cells were prepared as previously described [17].
- Anti-murine G-CSF antibodies (rabbit antiserum purified by protein A chromatography, Cytolab LTD, Weizmann Institute of Science, Israel) were used.
- Cyclophosphamide was purchased from Taro Pharmaceutical Industries Ltd. Haifa Bay, Israel.
- mice Female ICR, C57BL/6J or mice (BALB/C origin) mice aged 3 months, weighing an average of 25 gr were used. The mice were purchased from Harlan Laboratories, Jerusalem, ISRAEL. Standarized pelleted diet and tap water were supplied.
- normal cells were cultured in the presence adenosine or an adenosine agonist or antagonist.
- bone marrow cells obtained from the femur of C57BL/6J or ICR mice were first disaggregated by passing through a 25G needle. Then, the cells (3x10 5 cells/well, in 96 microtiter plates) were incubated with RPMI medium containing 10% fetal bovine serum (FBS) in the presence of adenosine (25 ⁇ M).
- FBS fetal bovine serum
- Adenosine or agonists to the A1 and A3 adenosine receptors - CPA (an A1RAg, 0.01 ⁇ M), CCPA (an A1RAg, 0.01 ⁇ M), or IB-MECA (an A3RAg, 0.01 ⁇ M) were added to the bone marrow cultures in the absence of adenosine; an A1 adenosine receptor antagonist, DPCPX (0.1 ⁇ M), was added to a bone marrow culture in the presence of adenosine (25 ⁇ M).
- [ 3 H]-Thymidine incorporation assay was used to evaluate the proliferation of the hone marrow cells. For this purpose, after 30 hours of incubation, each well was pulsed with 1 ⁇ Ci [ 3 H]-Thymidine. After a total of 48 hours of incubation, the cells were harvested and the [ 3 H]-Thymidine uptake was determined in an LKB liquid scintillation counter (LKB, Piscataway, NJ, USA). The results of this assay are depicted in Fig. 1 which shows that A1RAg or A3RAg have an effect on the production of G-CSF, that is similar to that obtained with adenosine.
- adenosine and its agonists exert their effect via stimulation of G-CSF production
- a further assay was conducted where anti-G-CSF antibodies (62.5ng/ml) were added to a culture of bone marrow cells in the presence of adenosine (25 ⁇ M), CPA (0.01 ⁇ M) or IB-MECA (0.01 ⁇ M).
- Cell proliferation was evaluated as described above.
- Fig. 2 shows that antibodies to G-CSF inhibited the stimulatory effect of adenosine and its agonists on the proliferation of bone marrow cells.
- the cumulative effect on the proliferation of bone marrow cells, when using a combination of an A1RAgm1 A3RAg, (CPA and IB-MECA) was evaluated.
- the assay was carried out similarly to that of the experiment the results of which are shown in Fig. 1.
- Cells, after being disaggregated, were incubated in the presence of either adenosine (25 ⁇ M), CPA (0.01 ⁇ M), IB-MECA (0.01 ⁇ M) or a combination of IB-MECA and CPA (each in a concentration of 0.01 ⁇ M) and further treated as described above.
- the results are depicted in Fig. 3A which shows increased combined effect of IB-MECA and CPA
- adenosine receptor antagonist In order to compare the effect of adenosine receptor antagonist on the proliferation of bone marrow cells, following the same methodology described above cells were incubated with adenosine alone or in combination with either DMPX (an A2RAn), DPCPX (an A1RAn), MRS-1220 (an A3RAn) or with a combination of DPCPX and MRS-1220. The results are shown in Fig. 3B. As can be seen blocking the A2 receptor by DN1PX also resulted in an increased proliferation of bone marrow cells which even exceeded that of adenosine alone. In comparison, proliferation with DPCPX or MRS-1220, reduced the increase by about 50% as compared to adenosine alone, while DPCPX in combination with MRS-1220 inhibited proliferation altogether.
- Example 2 Modulation of tumor cell growth by adenosine and its agonists
- Nb2-11C rat lymphoma cells (1.2x10 4 cells/ml) were incubated for 48 hours in 96 well microtiter plates with 1 ml RPMI medium containing 5% fetal bovine serum. Either 25 ⁇ M adenosine, 0.01 ⁇ M of an adenosine receptor agonists (CPA, an A1RAg; DPMA, an A2RAg or IB-MECA, an A3RAg) or 0.1 ⁇ M of an adenosine receptor antagonists (DPCPX, an A1RAn; DMPX, an A2RAn; or MRS-1220, an A3RAn) in combination with adenosine (25 ⁇ M) was added.
- CPA an adenosine receptor agonists
- DPMA an A1RAg
- IB-MECA an A3RAg
- DPCPX an adenosine receptor antagonists
- DPCPX an A1RAn
- Figs. 5A and 5B The results are shown in Figs. 5A and 5B, comparable to the inhibition with adenosine.
- the proliferation of Nb2-11C cells was markedly inhibited following incubation with IB-MECA, an A3RAg.
- the failure of CPA to inhibit the proliferation of these two tumor cells suggested that the adenosine A1 receptor is not involved in this activity.
- the inhibitory activity of both DMPA and 1B-MECA suggests the role of the A2 and the A3 adenosine receptors, respectively, in this inhibitory effect.
- Nb2-11C lymphoma or bone marrow cells were incubated in the presence of either adenosine, or IB-MECA.
- A3RAg is inhibiting the growth of tumor cells while stimulating the proliferation of bone marrow cells is depicted Figs. 7A and 7B.
- mice On day 5 and day 9 the mice were bled from the tail vain and blood samples were obtained for white blood cell (WBC) count. The results are depicted in Fig. 8.
- WBC white blood cell
- mice were sacrificed and melanoma tumor foci were counted in the lung.
- the results are depicted in Fig. 9.
- mice were treated with cyclophosphoamide (50 mg/kg body weight in 0.3 ml PBS). After 48 and 72 hours from administration of the cytotoxic drug, the mice were injected i.p. with adenosine (25 ⁇ g/kg body weight) or with IB-MECA (3 or 6 ⁇ g/kg body weight in 0.2 ml PBS) The number of white blood cells (WBC) and neutrophils was tested. The results are shown in Figs. 10A (WBCs) and 10B (neutrophils), respectively.
- mice treated with cyclophosphoamide only exhibited a decline in the number of peripheral blood leukocytes and neutrophils as compared to the group treated only with IB-MECA.
- adenosine or IB-MECA were administered, the total white blood cell count was restored with the latter having a very pronounced effect, yielding a complete recovery after 168 hours (7 days).
- Example 5 Adenosine A3 receptor agonist prevents weight loss in mice treated with a chemotherapeutic drug
- mice 4 groups of nude mice (BALB/C origin), 10 in each group were treated as follows:
- mice weight was measured at day 7, 10 and 14. The results are shown in Fig. 11.
- ICR mice were treated with doxorubicin (injection of 10 mg/kg i.p. in 0.5 ml PBS). After 24, 48 and 72 hours from administration of the cytotoxic drug, the mice were orally administered with C1-IB-MECA (6 ⁇ g/kg body weight). At 72 hours. 96 hours. 120 hours and 144 hours, the mice were sacrificed and blood samples were withdrawn. In addition, bone marrow cells were aspirated from the femur of the mice and a cell count of nucleated cells from this aspirated preparation was made, following staining of the preparation with Coumassile Blue.
- ICR mice were divided into six groups as follows:
- the CYP was injected intraperitoneally in 0.2 ml of PBS which served as the carrier.
- Cl-IB-MECA was given orally (in 0.2 ml PBS) at 48 hours and 72 hours following the administration of the cyclophophoamide.
- Anti-G-CSF antibodies were intravenously injected (in 0.2 ml PBS) 72 hours following the administration of the chemotherapeutic drugs.
- WBC White blood cells
- mice treated with cyclophosphoamide only showed a decline in the number of peripheral blood WBC.
- the WBC counts and the percentage of neutrophils were significantly higher in comparison to the chemotheapeutic treated group (results regarding transfer of neutrophils not shown).
- anti-G-CSF antibodies were administered to the control or the chemotherapy groups, an expected decline in the number of WBC was observed.
- Administration of anti-G-CSF antibodies to the mice treated with the combination of the chemotherapeutic drug and CI-IB-MECA cancelled the protective effect of Cl-IB-MECA, as can clearly be seen in Fig. 13.
- Example 8 CL-IB-MECA inhibits the development of HCT-116 human coon carconima in nude mice
- Tumors were established by subcutaneous injection of 1x10 6 HCT-116 human colon cancer cells to nude mice (BALB/C origin) (Harlan, Jerusalem, Israel). Mice were treated orally with 6 ⁇ g/kg body weight CI-IB-MECA (in 0.2 ml of PBS) every other day. Mice that were treated with the vehicle only (PBS). Each group consisted of 10 mice. Tumor growth rate was determined by measuring two orthogonal diameters of each tumor twice a week, and the tumor size was estimated according to the following formula: ⁇ /6[D 1 D 2 ]. The results are depicted in Fig. 14. As can be seen, in the treated group there is a marked inhibition of tumor growth.
- HCT-116 cells were injected subcutaneously to nude mice.
- 5-FU (30 mg/kg body weight, in 0.2 ml PBS) was intraperitoneally injected and subsequently in 4 additional consecutive days. Every other day, the mice were administered orally with 5 ⁇ g/kg body weight of C1-IB-MECA (in 0.2 ml of PBS). Mice that were treated either with the vehicle only (PBS) or with 5-FU served as control. Each group consisted of 10 mice. Tumor growth rate was determined by measuring two orthogonal diameters of each tumor twice a week, and the tumor size was estimated according to the following formula: ⁇ /6[D 1 D 2 ].
- Fig. 15 and 16 The results are depicted in Fig. 15 and 16. A marked inhibition of tumor growth was observed in the groups treated with 5-FU, Cl-IB-MECA and the combined therapy of Cl-IB-MECA and 5-FU. After 20 days a clear synergistic effect between Cl-IB-MECA and 5-FU in noting the tumor mass was seen, as depicted particularly in Fig. 16 (the results represented in Fig. 16 are those at day 30).
- Example 9 Cl-IB-MECA stimulates bone marrow cell proliferation through the induction of G-CSF production
- Bone marrow cells (3x10 6 celll/ml) were incubated in wells of 96 microtiter plates.
- Cl-IB-MECA at a final concentration of 10 nM was added with or without anti-G-CSF antibodies, at a final concentration of 0.05 and 0.5 ⁇ g/ml.
- Cell proliferation was measured by [ 3 H]-thymidine incorporation assay. The results are shown in Fig. 17.
- the anti-G-CSF antibodies inhibit the proliferation of the bone marrow cells in a dose-dependent manner.
- This experiment also shows that the action of Cl-IB-MECA is mediated through the G-CSF pathway (involving G-CSF secretion from the cells).
- Example 10 CI-IB-MECA inhibits tumor cell growth and stimulates bone marrow proliferation and differentiation
- B-16 melanoma cells (5x10 5 cells/ml) and bone marrow cells (3x 10 6 cells/ml) were incubated in wells of 96 microtiter plate.
- the culture consisted of RPMI medium supplemented with 10% FTS: C1-IB-MECA, at the concentration of 0.01 ⁇ M or 0.1 ⁇ M was added, with or without an antagonist of the adenosine A3 receptor, MRS-1523.
- Cell proliferation was measured by the [ 3 H]-thymidine incorporation assay mentioned before. The results are shown in Fig. 18.
- MRS-1523 the proliferation of both the B-16 melanoma cells and the bone marrow cells was unchanged versus control.
- the Cl-IB-MECA exerted an inhibitory effect on proliferation of the B-16 melanoma cells, and a proliferation stimulation effect on the bone marrow cells.
- Example 11 Cl-IB-MECA acts as a chemoprotective agent
- Murine bone marrow cells were cultured as described above. IB-MECA or Cl-IB-MECA were added to the cultures at a concentration of 1 or 10 nM, in the presence or absence of the A3RAn, MRS-1523. The antagonist was added at a concentration of 10 nM. The results are shown in Fig. 20.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
- The present invention is generally in the field of cancer and concerns a cancer therapy or a therapy intended to counter the side effect of cancer treatment.
- The following is a list of prior art which is considered to be pertinent for describing the state of the art in the field of the invention. Acknowledgement of these references herein will be made by indicating the number from their list below within brackets.
- 1. Linden J. The FASEB J. 5:2668-2676 (1991);
- 2. Stiles G. L. Clin. Res. 38:10-18 (1990);
- 3. Stolfi R.L., et al. Cancer Res. 43:561-566 (1983);
- 4. Belardinelli L. et al. Prog. Cardiovasc. Dis. 32:73-97 (1989);
- 5. Collis M. G., Pharmacol. Ther. 41:143-162 (1989);
- 6. Clark B. and Coupe M. Int. J. Cardiol. 23:1-10 (1989);
- 7. Dubey R. K. et al. Circulation 96:2656-2666 (1997)
- 8. Soderback U. et al. Clin. Sci. 81:691-694 (1994);
- 9. Gilbertsen R. B. Agents actions 22:91-98 (1987);
- 10. Bouma M. G. et al. J. Immunol. 153: 4159-4168 (1994);
- 11. Rozengurt E. Exp. Cell Res. 139:71-78 (1982);
- 12. Gonzales F.A., et al., PNAS USA 87:9717-9721 (1990);
- 13. Sandberg G. and Fredholm B.B., Thymus 3:63-75 (1981);
- 14. Pastan I.H. et al. Annu. Rev. Biochem. 44:491-495 (1975);
- 15.
WO 99/02143 - 16. Fishman P., et al. Cancer Res. 58:3181-3187 (1998);
- 17. Djaldetti M. et al. Clin. Exp. Metastasis 14:189-196 (1996);
- 18. Fishman P. et al. Cancer Research 58:3181-3187 (1998).
- Myelotoxicity is a prevailing, severe, complication of chemotherapy and is one of the factors that limit the administrable dose of the chemotherapeutic drug. It causes more life threatening patient morbidity and actual mortality than any other chemotherapeutic side effect and may result in an increased number of hospital stay days. In addition, drug induced myelosuppression limits the administration of larger, potentially more effective doses of chemotherapy to patients with malignancies. Several approaches to resolve this adverse event have included the use of lithium, prostaglandin E, interferon, lactoferrin and the growth factors granulocyte-macrophage colony stimulating factor (GM-CSF) and granulocyte-colony stimulating factor (G-CSF). To date, use of growth factors such as G-CSF is a standard therapy for cancer patients with neutropenia. It stimulates the proliferation and differentiation of hematopoietic progenitors and also controls the functional activities of neutrophils and macrophages. However, the G-CSF treatment is costly and as it is a recombinant protein, it has accompanying side effects.
- Adenosine, an endogenous purine nucleoside, is ubiquitous in mammalian cell types. Adenosine present in the plasma and other extracellular fluids mediates many of its physiological effects via cell surface receptors and is an important regulatory protein. It is released into the extracellular environment from metabolically active or stressed cells. It is known to act through its binding to specific G-protein associated A1, A2 and A3 membranal receptors(1-2). The interaction of adenosine with its receptors initiates signal transduction pathways, mainly the adenylate cyclase effector system, which utilizes cAMP as a second messenger. While A1 and A3 receptors, which are coupled with Gi proteins, inhibit adenylate cyclase and lead to a decrease in the level of intracellular cAMP, the A2 receptor, which is coupled to Gs proteins, activates adenylate cyclase, thereby increasing cAMP levels(3).
- Since specific surface receptors for adenosine are found in nearly all cells, almost all organ systems of the body are regulated to some extent by its local release. This includes regulation of the electrophysiological properties of the heart, sedation and suppression of neurotransmitter's release and regulation of rennin release and vascular tone in the kidney(4-7) . Adenosine exerts various effects on the immune system including anti-inflammatory activity through the inhibition of cytokine release, inhibition of platelet aggregation, induction of erythropoietin production and modulation of the lymphocyte function(8-10). Further, adenosine was found to play a role in the modulation of some central nervous system (CNS) functions, in wound healing, in diuresis and in controlling pain. It was also demonstrated that adenosine is capable of inducing proliferation in a wide range of normal cell types(11-14) . This modulation of cell growth is likely mediated through the adenylate cyclase effector system described above.
- In a recent study it was found that adenosine acts as a chemoprotective agent, which activity is likely related to its capability to stimulate bone marrow cell proliferation. Further, it was found that adenosine exerted an inhibitory effect on the proliferation of tumor cells, apparently through G0/G1 cell cycle arrest and reduction of the telomeric signal(17-18). The dual effect has turned adenosine into an attractive concept for cancer treatment.
- It was found that adenosine A3 receptor agonists (A3RAg) have a dual effect in that they inhibit proliferation of malignant cells on the one hand, and counter toxic side effects of chemotherapeutic drugs on the other hand. Specifically, the A3RAg compounds inhibit proliferation and growth of tumor cells, synergize with an anti-tumor cytotoxic drug in reducing the tumor load, induce proliferation and differentiation of bone marrow cells and white blood cells and counter toxic side effects of other drugs, particularly chemotherapeutic drugs. Furthermore, it was discovered that the A3RAg exerts these activities by a variety of forms of administration including parenteral administration and particularly oral administration. It was further found that some of the A3RAg activity may be mimicked by other agonists and antagonists of the adenosine A1 or A2 receptors: the adenosine A1 receptor agonists (A1RAg) shares with the A3RAg its ability to induce G-CSF secretion; adenosine A2 receptor agonist (A2RAg) shares with the A3R.A,g its ability to inhibit proliferation of malignant cells; and the adenosine A2 receptor antagonist (A2RAn) shares with the A3RAg its ability to counter toxic side effects of drugs, e.g. treat or prevent leukopenia.
- The invention relates in its broadest sense, to the use of an active ingredient to yield one of the following therapeutic/biological effects: inducing production or secretion of G-CSF within the body; prevention or treatment of toxic side effects of a drug or prevention or treatment of leukopenia, particularly drug-induced leukopenia; and inhibition of abnormal cell growth and proliferation. The active ingredient may be an A3RAg or an agonist or antagonist of the adenosine receptor system which can yield one of these therapeutic effects, achieved by the use of the A3RAg.
- The first embodiment, to be referred to herein as the "G-CSF-inducing embodiment" involves the use of an active ingredient, which may be an A3Rag to yield secretion of the G-CSF within the body of a treated subject. G-CSF is known to stimulate proliferation and differentiation of hematopoietic progenitors and controls the functional activities of neutrophils and macrophages. Thus, a G-CSF-inducing agent such as those mentioned above, may have a high therapeutic value, for example, in countering (i.e. preventing, reducing or ameliorating) myelotoxicity.
- Provided in accordance with this embodiment is a method for inducing G-CSF secretion within the body of a subject, comprising administering to the subject an effective amount of an active ingredient A3RAg. In accordance with this embodiment there is further provided a method for the therapeutic treatment, comprising administering to a subject in need an effective amount of said active ingredient for achieving a therapeutic effect, the therapeutic effect comprises induction of G-CSF production or secretion. Still further provided by this embodiment is use of said active ingredient for the manufacture of a pharmaceutical composition for inducing G-CSF secretion. Also provided by this embodiment is a pharmaceutical composition for inducing production or secretion of G-CSF within the body, comprising a pharmaceutically acceptable carried an effective amount of said active ingredient.
- In accordance with another embodiment, to be referred to herein at times as the "Leukopenia-prevention embodiment" or more specifically as the "neutropenia-prevention embodiment", an active ingredient which may be an A3RAg, is used for the prevention or treatment of leukopenia, which may result from myelotoxicity.
- In accordance with this embodiment there is provided a method for inducing proliferation or differentiation of bone marrow or white blood cells in a subject, comprising administering to the subject an effective amount of an active ingredient A3RAg. Also provided by this embodiment is a method for prevention or treatment of leukopenia, comprising administering to a subject in need an effective amount of said active ingredient. Further provided in accordance with this embodiment is use of said active ingredient for the manufacture of a pharmaceutical composition for inducing proliferation or differentiation of bone marrow or white blood cells. Still further provided in accordance with this embodiment is use of said active ingredient for the manufacture of a pharmaceutical composition for the prevention or treatment of leukopenia. The pharmaceutical composition can particularly be used for prevention or treatment of leukopenia.
- In accordance with a related embodiment, to be referred to herein as the "toxicity-preventing embodiment" the abovementioned active ingredient, namely A3RAg, is used to counter toxic side effects of drugs, such as chemotherapeutic drugs or nemoleptic drugs.
- In accordance with this latter embodiment there is thus provided a method for prevention or treatment of toxic side effects of a drug, comprising administering to a subject in need an effective amount of an active ingredient A3RAg. Also provided in accordance with this embodiment is use of said active ingredient for the manufacture of a pharmaceutical composition for the prevention or treatment of drug-induced toxicity. Still further provided by this embodiment is pharmaceutical composition for prevention or treatment of toxic side effects of a drug, comprising an effective amount of said active ingredient and a pharmaceutically acceptable carrier.
- For the purpose of countering drug-induced leukopenia or drug-induced toxic side effects in general, it is at times desirable to formulate a drug which has such toxic side effects together with said active ingredient for combined administration of the two. The invention thus also provides a pharmaceutical composition comprising, in combination a drug that can cause toxic side effect in a subject treated thereby and said active ingredient; as well as use of said active ingredient for the manufacture of such a pharmaceutical composition. Said active ingredients included in said composition being an amount effective for prevention or treatment of the toxic side effects.
- In accordance with yet another embodiment, to be referred to herein as the "proliferation-inhibiting embodiment", an active ingredient, which may be an A3RAg, is used for selectively inhibiting abnormal cell growth, e.g. tumor cell growth.
- In accordance with this embodiment there is provided a method for inhibiting abnormal cell growth in a subject, comprising administering to the subject a therapeutically effective amount of an active ingredient A3RAg. Also provided in accordance with this embodiment is use of said active ingredient for the manufacture of a pharmaceutical composition for inhibiting abnormal cell growth. Still further provided by this embodiment is a pharmaceutical composition for inhibiting abnormal cell growth, comprising said active ingredient, and a pharmaceutically acceptable carrier.
- In one embodiment the administration of the active ingredient is intended to achieve dual therapeutic effect: inhibition of abnormal cell growth and reduction of toxic side effects of a drug causing such effects.
- The preferred active ingredient in accordance with the invention is an A3RAg. The preferred route of administration of the active ingredient, in accordance with the invention is the oral administration route. However, this preference does not exclude other active ingredients neither other administration routes of the active ingredients.
- The dosage of the active ingredient, particularly where the active ingredient is an A3Rag, is preferably less than 100 µg/kg body weight, typically less than 50 µg and desirably within the range of 1-10 µg/kg body weight.
- The invention relates to the use of an effective amount of an active ingredient for the preparation of a pharmaceutical composition for countering drug-induced myelotoxicity, wherein said active ingredient is an adenosine A3 receptor agonist (A3RAg), which exerts its prime effect through the A3 receptor and has the following general formula (I):
- Y is oxygen, sulfur or CH2;
- X1 is H, C1-C10 alkyl, RaRbNC(=O)- or HORc-, wherein Ra and Rb may be the same or different and are selected from the group consisting of hydrogen, C1-C10 alkyl, amino, C1-C10 haloalkyl, C1-C10 aminoalkyl, C1-C10 BOC-aminoalkyl, and C4-C10 cycloalkyl or are joined together to form a heterocyclic ring containing two to five carbon atoms, and Rc is selected from the group consisting of C1-C10 alkyl, -NH-, C1-C10 haloalkyl, C1-C10 aminoalkyl, C1-C10 Boc-aminoalkyl and C3-C10 cycloalkyl;
- X2 is H, hydroxyl, C1-C10 alkylamino, C1-C10 alkylamido or C1-C10 hydroxyalkyl;
- X3 and X4 each independently are hydrogen, hydroxyl, amino, amido, azido, halo, alkyl, alkoxy, carboxy, nitrilo, nitro, trifluoro, aryl, alkaryl, thio, thioester, thioether, -OCOPh,* -OC(=S)OPh or both X3 and X4 are oxygen connected to >C=S to form a 5-membered ring, or X2 and X3 form the ring of formula (III):
- R2 is selected from the group consisting of hydrogen, halo, C1-C10 alkylether, amino, hydrazido, C1-C10 alkylamino, C1-C10 alkoxy, C1-C10 thioalkoxy, pyridylthio, C2-C10 alkenyl; C2-C10 alkynyl, thio, and C1-C10 alkylthio; and
- R3 is a -NR4R5 group with R4 being hydrogen or a group selected from alkyl, substituted alkyl or aryl-NH-C(Z)-, with Z being O, S, or NRa with Ra having the above meanings,
- and R5, where R4 is hydrogen, is selected from the group consisting of Rand S-1-phenylethyl, benzyl, phenylethyl or anilide groups unsubstituted or substituted in one or more positions with a substituent selected from the group consisting of C1-C10 alkyl, amino, halo, C1-C10 haloalkyl, nitro, hydroxyl, acetoamido, C1-C10 alkoxy, and sulfonic acid or a salt thereof; or R5 is benzodioxanemethyl, fururyl, L-propylalanyl-aminobenzyl, β-alanylamino-benzyl, T-BOC-β-alanylaminobenzyl, phenylamino, carbamoyl, phenoxy or C1-C10 cycloalkyl; or R5 is a group of the following formula:
- or a suitable salt of the compound defined above, e.g. a triethylammonium salt thereof; or
- when R4 is a group selected from alkyl, substituted alkyl, or aryl-NH-C(Z)-, then, R4 is selected from the group consisting of substituted or unsubstituted heteroaryl-NR6-C(Z)-, heteroaryl-C(Z)-, alkaryl-NR6-C(Z)-, alkaryl-C(Z)-, aryl-NR-C(Z)- and aryl-C(Z)-;
-
- In a preferred embodiment, the active ingredient is an N6-benzyladenosine-5'-uronamide derivative.
- Preferably, the active ingredient is selected from N6-2-(4-aminophenyl)ethyladenosine (APNEA), N6-(4-amino-3-iodobenzyl) adenosine-5'-(N-methyluronamide) (AB-MECA), N6-(3-iodobenzyl)-adenosine-5'-N-methyl-uronamide (IB-MECA) and 2-chloro-N6-(3-iodobenzyl)-adenosine- 5'-N-methyl-uronamide (CI-IB-MECA).
- In another embodiment, the active ingredient is N6-benzyl- adenosine-5'-alkyluronamide-N1-oxide or N6-benzyladenosine-5'-N-dialyl-uron- amide-N1oxide.
-
- X is O or S;
- R6 is RaRbNC(=O)- or HORc-, wherein
- Ra and Rb may be the same or different and are selected from the group consisting of hydrogen, C1-C10 alkyl, amino, C1-C10 haloalkyl, C1-C10 aminoalkyl, and C3-C10 cycloalkyl, or are joined together to form a heterocyclic ring containing two to five carbon atoms; and
- Rc is selected from C1-C10 alkyl, -NH-, C1-C10 haloalkyl, C1-C10 aminoalkyl, C1-C10 Boc-aminoalkyl and C3-C10 cycloalkyl;
- R7 and R8 may be the same or different and are selected from the group consisting of C1-C10 alkyl, C3-C10 cycloalkyl, R- or S-1-phenylethyl, an unsubstituted benzyl or anilide group, and a phenylether of benzyl group substituted in one or more positions with a substituent selected from the group consisting of C1-C10 alkyl, amino, halo, C1-C10 haloalkyl, nitro, hydroxyl, acetamido, C1-C10 alkoxy, and sulfonic acid;
- R9 is selected from the group consisting of halo, benzyl, phenyl, C3-C10 cycloalkyl, and C1-C10 alkoxy;
- In one embodiment, the drug is a chemotherapeutic drug given to the subject within the framework of anti-cancer treatment.
- The present invention also relates to the use of an effective amount of an active ingredient for the preparation of a pharmaceutical composition for inducing proliferation or differentiation of bone marrow or white blood cells, wherein the active ingredient is an adenosine A3 receptor agonist (A3RAg), which exerts its prime effect through the A3 receptor and is as defined above.
- The present invention further relates to the use of an effective amount of an active ingredient for the preparation of a pharmaceutical composition for the prevention or treatment of leukopenia, the active ingredient being an adenosine A3 receptor agonist (A3RAg), which exerts its prime effect through the A3 receptor and is as defined above.
- In one embodiment, the leukopenia is drug- induced leukopenia.
- In addition, the present invention relates to the use of an effective amount of an active ingredient for the preparation of a pharmaceutical composition for the prevention or treatment of toxic side effects of a drug, the active ingredient being an adenosine A3 receptor agonist (A3RAg), which exerts its prime effect through the A3 receptor and is as defined above.
- In one embodiment, the toxic side effect is manifested by weight loss.
- In another embodiment, the drug is a chemotherapeutic drug.
- In yet another embodiment, the pharmaceutical composition is for elevating the level of circulating leukocytes in a subject.
- The present invention also relates to the use of an effective amount of an active ingredient being an adenosine A3 receptor agonist (A3RAg), which exerts its prime effect through the A3 receptor, for the manufacture of a pharmaceutical composition, wherein said manufacture comprises mixing said active ingredient with a drug that can cause a toxic side effect in a treated subject.
- In one embodiment, the drug is a chemotherapeutic drug.
- The present invention also relates to the use of an effective amount of an active ingredient for the preparation of a pharmaceutical composition for selectively inhibiting abnormal cell growth, the active ingredient being an adenosine A3 receptor agonist (A3RAg), which exerts its prime effect through the A3 receptor and is as defined above.
- In one embodiment, the abnormal cell growth is the growth or proliferation of tumor cells.
- In another embodiment, the abnormal cell-growth is associated with an autoimmune disease.
- In a further embodiment, the pharmaceutical composition is intended for administration in combination with a chemotherapeutic drug.
- The present invention further relates to the use of an effective amount of an A3RAg, which exerts its prime effect through the A3 receptor, for the preparation of a pharmaceutical composition for the treatment of cancer in a subject, the pharmaceutical composition yielding a dual effect in both inhibiting proliferation of cancer cells and countering toxic side effects of a chemotherapeutic drug treatment of the same subject, wherein the active ingredient is as defined above.
- In one embodiment, the active ingredient synergizes with said drug to yield a stronger anti-tumor effect
- In certain preferred embodiments, the active ingredient is formulated for oral administration.
- In certain preferred embodiments, the dosage of the A3RAg is < 100 µg/kg body weight, preferably < 50 µg/kg body weight, more preferably within the range of 1-10 µg/kg body weight.
- A novel therapeutic use is provided for certain active agents, particularly adenosine receptor agonists and antagonists. By one embodiment, the G-CSF-inducing embodiment, some such agents are used to mediate the production and secretion of G-CSF from cells. In accordance with another embodiment, the toxicity-preventing embodiment, some such agents are used to counter toxic side effects of drugs, e.g. chemotherapeutic or nemoleptic drugs. In a further embodiment, the leukopenia-prevention embodiment, some such agents are used to counter leukopenia, particularly drug induced leukopenia. In accordance with yet another embodiment, the proliferation-inhibition embodiment, some such agents are used to selectively inhibit abnormal cell growth.
- The term "leukopenia" as used herein refers to the reduction in the circulating white blood cell count. While leukopenia is usually characterized by a reduced number of blood neutrophils (neutropenia), at times, a reduced number of lymphocytes, monocytes, eosinophils or basophils may be detected.
- Leukopenia which may arise from the reduced production or excessive splenic sequestration of neutrophils, may result from a hereditary and congenital diseases. However it is mainly observed after treatment with drugs, such as cytoreductive cancer drugs, antithyroid drugs, phenothiazines, anticonvulsants, penicillins, sulfonamides, and chloramphenicol. Some antineoplastics cause leukopenia as a predictable side effect.
- In the following, a reduction in leukocyte count or neutrophil count by drugs will be referred to herein, as "drug-induced leukopenia" or "drug-induced neutropenia". Furthermore, whenever mention is made to leukopenia, it should be understood as referring particularly to "neutropenia".
- Further, the term "prevention or treatment of leukopenia" should be understood as a procedure whereby the reduction in leukocyte cell count which may otherwise occur, is reduced, totally prevented or if such reduction has occurred, a procedure which gives rise to increase in the leukocyte cell count. Leukopenia is manifested by a variety of side effects such as an increased possibility to infection by significant infectious agents and others. The term "prevention or treatment of leukopenia " should also be understood as meaning an improvement in such parameters which may occur as a result of leukopenia.
- The pharmaceutically or therapeutically "effective amount" for purposes herein is determined by such considerations as may be known in the art. The amount must be effective to achieve the desired therapeutic effect which depends on the type and mode of treatment. As is clear to the artisan, the amount should be effective to obtain the improvement of survival rate, to obtain a more rapid recovery, to obtain the improvement or elimination of symptoms or any other indicators as are selected as appropriate measures by those skilled in the art. When, for example, said active ingredient is administered to induce G-CSF production, an effective amount of the active ingredient may be an amount which leads to production and secretion of G-CSF from peripheral blood mononuclear cells, endothelial cell or fibroblast, in which it was produced, thereby, for example, stimulating the maturation of granulocytes progenitors into mature neutrophils. Where the active ingredient is administered to counter drug-induced leukopenia, an effective amount of the active ingredient may be an amount which protects the individual against the drug-induced reduction in the count of leukocytes, particularly neutrophils; an amount of the active ingredient which can give rise to an increase in an already decreased level of such cells, e.g. restore the level to a normal level or sometimes even above; etc. Where the active ingredient is administered in order to reduce toxic side effect of a drug, the amount of the active ingredient may, for example, be an amount effective in reduction of weight loss resulting from the drug administered. Where the active ingredient is administered in order to inhibit abnormal cell growth, as detailed hereinafter, an effective amount may be an amount which will inhibit the proliferation of such cells in the treated subject and even eliminate the tumor. Where the active ingredient is administered in order to potentiate the effect of an anti-cancer chemotherapeutic drug, an effective amount may be an amount which either increases the cancer specific toxicity of the chemotherapeutic treatment; an amount which is effective in reducing the amount of the chemotherapeutic drug or drug combination required to achieve a desired effect of the chemotherapeutic drug or drug combination, i.e. reduction of the tumor load; etc. An example of an effective amount is a daily administration of A3RAg less than 100 µg/kg body weight, typically less than 50 µg/kg body weight and optionally even less than 10 µg/kg body weight, e.g. about 3-6 µg/kg body weight. Such an amount of A3RAg is typically administered in a single-daily dose although at times a daily dose may be divided into several doses administered throughout the day or at times several daily doses may be combined into a single dose to be given to the patient once every several days, particularly if administered in a sustained release formulation.
- The active ingredient according to the invention is an A3RAg. The A3RAg is any agonist which binds to A3 receptors and activates them to yield a therapeutic effect of the present invention. It should be noted that at times, an A3RAg may also interact with other receptors, e.g. with the
A 1 and A2 receptors. However, the A3RAg used in accordance with the invention exerts its prime effect through the A3 receptor (namely there may also be minor effects exerted through interaction with other adenosine receptors). - By one embodiment, the active ingredient according to the invention is a nucleoside derivative. By the term "nucleoside" it is meant any compound comprising a sugar, preferably ribose or deoxyribose, or a purine or pyrimidine base or a combination of a sugar with a purine or pyrimidine base preferably by way of N-glycosyl link. The term "nucleoside derivative" will be used to denote herein a naturally occurring nucleoside as define hereinabove, a synthetic nucleoside or a nucleoside which underwent chemical modifications by way of insertion/s, deletion/s or exocyclic and endocyclic substitution/s of group/s therein or conformational modifications which provide a derivative with the desired biological effect.
- In accordance with the invention the active ingredient is an A3RAg.
-
- Y is oxygen, sulfur of carbon atoms;
- X1 is H, C1-C10 alkyl, RaRbNC(=O)- or HORc-, wherein Ra and Rb may he the same or different and are selected from the group consisting of hydrogen, C1-C10 alkyl, amino, C1-C10 haloalkyl, C1-C10 aminoalkyl, C1-C10 BOC-aminoalkyl, and C3-C10 cycloalkyl or are joined together to form a heterocyclic ring containing two to five carbon atoms, and Rc is selected from the group consisting of C1-C10 alkyl, amino, C1-C10 haloalkyl, C1-C10 aminoalkyl, C1-C10 BOC-aminoalkyl, and C3-C10 cycloalkyl;
- X2 is H, hydroxyl, C1-C10 alkylamino, C1-C10 alkylamido or C1-C10 hydroxyalkyl;
- X3 and X4 each independently are hydrogen, hydroxyl, amino, amido, azido, halo, alkyl, alkoxy, carboxy, nitrilo, nitro, trifluoro, aryl, alkaryl, thio, thioester, thioether, -OCOPh, -OC(=S)OPh or both X3 and X4 are oxygen connected to >C=S to form a 5-membered ring, or X2 and X3 form the ring of formula (III):
- R2 is selected from the group consisting of hydrogen, halo, C1-C10 alkylether, amino, hydrazido, C1-C10 alkylamino, C1-C10 alkoxy, C1-C10 thioalkoxy, pyridylthio, C2-C10 alkenyl; C2-C10 alkynyl, thio, and C1-C10 alkylthio; and
- R3 is an -NR4R5 group, with R4 being hydrogen or a group selected from alkyl, substituted alkyl or aryl-NH-C(Z)-, with Z being O, S, or NRa with Ra having the above meanings,
- and R5, where R4 is hydrogen, is selected from the group consisting of R- and S-1-phenylethyl, benzyl, phenylethyl or anilide groups unsubstituted or substituted in one or more positions with a substituent selected from the group consisting of C1-C10 alkyl, amino, halo, C1-C10 haloalkyl, nitro, hydroxyl, acetoamido, C1-C10 alkoxy, and sulfonic acid or a salt thereof; or R4 is benzodioxanemethyl, fururyl, L-propylalanylaminobenzyl, β-alanylamino- benzyl, T-BOC-β-alanylaminobenzyl, phenylamino, carbamoyl, phenoxy or C1-C10 cycloalkyl, or R5 is a group of the following formula:
-
- Preferred active ingredients according to this embodiment of the invention may generally be referred to as N6-benzyladenosine-5'-uronamides and derivatives thereof found to be A3-selective adenosine receptor agonists. Examples for such derivatives arc N6-2-(4-aminophenyl)ethyladenosine (APNEA), N6-(4-amino-3-iodobenzyl) adenosine-5'-(N-methyluronamide) (AB-MECA) and 1-deoxy-1-{6-[({3-iodophenyl} methyl)amino]- 9H-purine-9-yl}-N-methyl-β-D-ribofuranuron-amide the latter also referred to in the art as N6-3-idobenzyl -5'-methylcarboxamidoadenosine, N6-(3-idobenzyl) adenosine-5'-N-methyl-uronamide and herein above and below by the abbreviation IB-MECA or a chlorinated derivative of IB-MECA (R2=Cl), referred to herein as C1-IB-MECA, IB-MECA and C1-IB-MECA being currently particularly preferred.
- According to another embodiment of the invention, the active ingredient may be adenosine derivative generally referred to as N6-benzyl-adenosine-5'-alkyluronamide-N'-oxide or N6-benzyladenosine-5'-N- dialyluron-amide -N1-oxide.
-
- X is O or S;
- R6 is RaRbNC(=O)- or HORc-, wherein
- Ra and Rb may be the same or different and are selected from the group consisting of hydrogen, C1-C10 alkyl, amino, C1-C10 haloalkyl, C1-C10 aminoalkyl, and C3-C10 cycloalkyl, or are joined together to form a heterocyclic ring containing two to five carbon atoms; and
- Rc is selected from C1-C10 alkyl, amino, C1-C10 haloalkyl, C1-C10 aminoalkyl, C1-C10 BOC-aminoalkyl and C3-C10 cycloalkyl;
- R7 and R8 may be the same or different and are selected from the group consisting of C1-C10 alkyl, C1-C10 cycloalkyl, R- or S-1-phenylethyl, an unsubstituted benzyl or anilide group, and a phenylether of benzyl group substituted in one or more positions with a substituent selected from the group consisting of C1-C10 alkyl, amino, halo, C1-C10 haloalkyl, nitro, hydroxyl, acetamido, C1-C10 alkoxy, and sulfonic acid;
- R9 is selected from the group consisting of halo, benzyl, phenyl, C3-C10 cyclalkyl, and C1-C10 alkoxy;
- Some of the above defined compounds and their synthesis procedure may be found in detail in
US 5,688,774 ;US 5,773,423 ,US 6,048,865 ,WO 95/02604 WO 99/20284 WO 99/06053 - The active ingredient in accordance with the invention may be as defined above or may be in the form of salts or solvates thereof, in particular physiologically acceptable salts and solvates thereof Further, when containing one or more asymmetric carbon atoms, the active ingredient may include isomers and diastereoisomers of the above active ingredients or mixtures thereof.
- Pharmaceutically acceptable salts of the above active ingredients include those derived from pharmaceutically acceptable inorganic and organic acids. Examples of suitable acids include hydrochloric, hydrobromic, sulphoric, nitric, perchloric, fumaric, maleic, phosphoric, glycollic, lactic, salicylic, succinic, toluene-p-sulfonic, tartaric, acetic, citric, methanesulfonic, formic, benzoic, malonic, naphthalene-2-sulfonic and benzenesulfonic acids.
- The active ingredient may be administered as a non-active substance (e.g. pro-drug) and be made active only upon further modification/s by a natural process at a specific site in the subject. In any case, the derivative will be such that the therapeutic functionality of the pharmaceutical composition of the invention, is preserved. Such pro-drugs are also encompassed by the term "active ingredient" as used herein. Similarly, the terms "A3RAg", "A1RAg'' "Á1RAn" "A2RAg" and "A2RAn should be understood as encompassing pro-drugs which, although a priori, lack the agonistic or antagonistic activity (as the case may be), become active in vivo.
- The A3RAg in accordance with the invention may be chosen by screening for such compounds which qualitatively have an activity resembling that of IB-MECA. For example, such compounds for use in accordance with the leukopenia-inhibiting embodiment may be screened based on their ability to stimulate proliferation of bone marrow or white blood cells and subsequently based on their ability to exert this activity in vivo. For use in the proliferation-inhibition embodiment, compounds may be screened for their ability to inhibit proliferation of tumor cells as well as subsequently to exert this activity in vivo.
- The A1RAn and A2RAn may be tested for their activity and screened for use in therapy in a similar manner, mutatis mutandis, to that described for A3RAg.
- The pharmaceutical composition of the invention may comprise the active ingredient as such, but may be combined with other ingredients which may be a pharmaceutically acceptable carrier, diluent, excipient, additive and/or adjuvent, as known to the artisan, e.g. for the purposes of adding flavors, colors, lubrication or the like to the pharmaceutical composition. Evidently, the pharmaceutically acceptable carrier/s, diluent/s, excipient/s, additive/s employed according to the invention generally refer to inert, non-toxic solid or liquid fillers, diluents or encapsulating materials which preferably do not react with the compounds within the composition of the invention.
- Further, the active ingredient may also be administered in combination with a chemotherapeutic drug, particularly in the case of the leukopenia prevention embodiment. Thus the pharmaceutical composition according to the invention may comprise, in addition to said active ingredient a chemotherapeutic drug. According to one embodiment of the invention, the chemotherapeutic drug is an anti-cancer chemotherapeutic drug. It should be understood that by the term it is meant any cytotoxic drug or a cocktail comprising a combination of two or more cytotoxic drugs given to a patient for the purpose of reducing the patient's tumor mass.
- One finding is that the A3RAg is orally bioavailable and exerts its dual activity (reducing abnormal cell proliferation and preventing or reducing leukopenia) when orally administered. Thus, according to one preferred embodiment, the pharmaceutical composition of the invention is formulated for oral administration. Such an oral composition may further comprise a pharmaceutically acceptable carrier, diluent, excipient, additive or adjuvant suitable for oral administration.
- Within the scope of the G-CSF-inducing embodiment, the pharmaceutical compositions disclosed are particularly used for increasing the level of G-CSF secreted from the cells. Such compositions may be used to accelerate the neutrophil recovery after chemotherapy and bone marrow transplantation or to inhibit abnormal cell growth. To date, such treatments include administration of the growth factor it self, which are known to have undesired side effects. All the more so, the average cost per course of G-CSF therapy is known to be very high.
- Within the scope of the leukopenia-prevention embodiment or the toxicity-preventing embodiment of the present invention, the pharmaceutical composition disclosed are particularly used for elevating the level of circulating leukocyte cells in a subject or countering other toxic effects, such as weight loss. This aspect of the invention is applicable in a variety of clinical situations. It is evident that a reduced level of circulating leukocytes and particularly neutrophils may result in a weakened immune system. An example of a weakened immune system which may be treated in accordance with this aspect of the invention, is such which often occurs in advanced stages of cancer or that resulting from drug-induced leukopenia or drug-induced neutropenia.
- The proliferation-inhibiting embodiment is useful for the treatment of a variety of abnormalities associated with the abnormal cell growth such as cancer, psoriasis and some autoimmune diseases. In particular, the composition of the invention is employed for inhibiting proliferation of tumor cells, preferably within the framework of anti-cancer therapy.
- When treating lymphoma cells with an A3RAg the inhibition of proliferation of these cells was more pronounced than that obtained with adenosine or the 'A1' or 'A2' agonists, although some activity was also observed with the A2RAg (see for example Fig. 5A). These results show that inhibition of tumor cell proliferation should be ascribed mainly to the binding of A3RAg to its corresponding receptor but may also be mimicked to some extent by an A2RAg. The above surprising results thus offers a new therapeutic target for future anti-cancer cytostatic drugs.
- A3RAgs were further found to be potent in inhibiting growth of tumor cells, other than lymphoma, e.g. melanoma or colon carcinoma (see for example Fig. 6). A man versed in the art would clearly appreciate the advantage of treating a subject with a non-specific anti-cancer drug capable of inhibiting growth of the abnormally dividing cells while concomitantly being capable restoring the immune system of the subject by inducing bone marrow cell proliferation.
- Figs. 7A-7B, for example, show the differential effect of A3RAg. In this particular case, the effect of IB-MECA, on tumor and normal cells was evaluated. The more pronounced effect obtained using A3RAg, as compared to adenosine, is also clearly presented by these results. The therapeutic effect of A3RAg was reversed when an A3 receptor antagonist, MRS-1220, was employed.
- The in vivo studies confirmed the in vitro results which demonstrated a chemoprotective effect of A3R.Ag on mice which were treated simultaneously with A3RAg and with a cytotoxic agent as compared to mice treated only with the cytotoxic drug (see for example Fig. 8). Further, a decrease in the number of foci in the A3RAg-treated mice was observed indicating the chemotherapeutic activity of A3RAg (see for example Fig. 9). Figures 10A-10B as well as 19A and 19B, for example, show that tumor-bearing mice treated only with the cytotoxic drug exhibited a decline in the number of peripheral blood leukocytes and neutrophils, while administration of A3RAg after chemotherapy, resulted in the restoration of the total white blood cell count yielding an increase in the percentage of neutrophils.
- Thus, it may be concluded that A3RAg has a dual therapeutic function as it acts both as a chemotherapeutic agent as well as a chemoprotective agent. It is clear that use of A3RAg for this dual effect is also within the scope of the present invention.
- In any case, the pharmaceutical compositions of the invention are administered and dosed in accordance with good medical practice, taking into account the clinical condition of the individual patient, the site and method of administration, scheduling of administration, patient's age, sex, body weight and other factors known to medical practitioners.
- The composition of the invention may be administered in various ways. It can be administered orally, subcutaneously or parenterally including intravenous, intraarterial, intramuscular, intraperitoneally or by intranasal administration, as well as by intrathecal and infusion techniques known to the man versed in the art.
- As known, a treatment course in humans is usually longer than in animals, e.g. mice, as exemplified herein. The treatment has a length proportional to the length of the disease process and active agent effectiveness. The therapeutic regimen involved single doses or multiple doses over a period of several days or more. The treatment generally has a length contingent with the course of the disease process, active agent effectiveness and the patient species being treated.
- When administering the compositions of the present invention parenterally, it will generally be formulated in a unit dosage injectable form (solution, suspension, emulsion). The pharmaceutical formulation suitable for injection includes sterile aqueous solutions or dispersions and sterile powders for reconstitution into sterile injectable solutions or dispersions. The carrier employed can be a solvent or dispersing medium containing, for example, water, ethanol, polyol (tor example, glycerol, propylene glycol, lipid polyethylene glycol and the like), suitable mixtures thereof and vegetable oils.
- Non-aqueous vehicles such as cottonseed oil, sesame oil, olive oil, soybean oil, corn oil, sunflower oil, or peanut oil and ester, such as isopropyl myristate, may also at times be used as solvent systems for the active ingredient.
- Additionally, various additives which enhance the stability, sterility and isotonicity of the compositions, including antimicrobial preservatives, antioxidants, chelating agents and buffers can be added. Prevention of the action of microorganisms can be ensured by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid and the like.
- For the purpose of oral administration, the active ingredient may be formulated in the form of tablets, suspensions, solutions, emulsions, capsules, powders, syrups and the like, are usable and may be obtained by techniques well known to the pharmacists.
- The present invention is defined by the claims, the contents of which are to be read as included within the disclosure of the specification, and will now be described by way of example with reference to the accompanying Figures. It is to be understood, that the terminology which has been used is intended to be in the nature of words of description rather than limitation.
- In order to understand the invention and to see how it may be carried out in practice, a preferred embodiment will now be described, by way of non-limiting example only, with reference to the accompanying drawings, in which:
- Fig. 1 is a bar graph showing results of an in vitro assay in which the effect of adenosine (Ad), DPCPX (an A1RAn), CPA and CCPA (both A1RAg) or IB-MECA (an A3RAg) on G-CSF production is shown. Cultures treated with modified RPMI served as the control. The results are presented in terms of percent of control (control = 100%):
- Fig. 2 is a bar graph showing results, obtained by [3H]-thymidine incorporation assay, of an experiment in which stimulation of proliferation of bone marrow cells by either adenosine, CPA or IB-MECA, with ((+) G-CSF Ab - light-colored columns) or without antibodies against G-CSF ((-) G-CSF Ab - dark columns) was tested. The results show the neutralization effect of the anti-g-CSF antibodies. The results are represented in terms of percent increase over control (control = 0%).
- Fig. 3A and 3B are two bar graphs showing results, obtained by a [3H]-thymidine incorporation assay, of an experiment, in which proliferation of bone marrow cells was tested in the presence of adenosine, an adenosine receptor agonists (Fig. 3A) or adenosine in combination with an adenosine receptor antagonists (Fig. 3B). The receptor agonists tested (Fig. 3A) are CPA (an A1RAg) and IB-MECA (an A3RAg); the receptor antagonists tested (Fig. 3B) were DPCPX (an A1RAn), DMPX (an A2RAn) and MRS (an A3RAn). The results are presented in terms of percent increase in thymidine incorporation over control (control = 0%).
- Fig. 4 is a bar graph showing results of an in vitro experiment in which the proliferation of bone marrow cells under three different concentrations of IB-MECA (0.01 µM, 0.1 µM and 1.0 µM) was tested. These results are presented in terms of the [3H]-thymidine incorporation - percent above control (control = 0%). The numbers below the bars are the IB-MECA concentrations (µM).
- Figs. 5A and 5B are bar graphs showing results of two experiments, both carried out in vitro and being based on cell count assays, in which the effect of growth of lymphoma cells (Nb2-11C) by adenosine and its antagonist was tested. In the experiment shown in Fig. 5A, the effect on lymphoma cell growth by adenosine. CPA (an A1RAg), DMPA (an A2RAg) or IB-MECA (an A3RAg) was tested. In the experiment shown in Fig. 5B, the effect on the lymphoma cell growth by adenosine, DPCPX (an A1RAn), DMPX (an A2RAn) or MRS-1220 (an A3RAn) was tested. RPMI-treated lymphoma cells serve as control. The results are depicted as % inhibition of growth over that of control (control = 0%).
- Fig. 6 is a bar graph showing results of an in vitro assay in which growth of different tumor cell types (B16 melanoma, HTC-116 colon carcinoma, Nb2-11C lymphoma) was inhibited in the presence of the A3RAg IB-MECA. RPMI-treated cells served as control. The results are presented as percent inhibition over control (control = 0%).
- Fig. 7A and 7B are bar graphs showing the results of an in vitro assay in which the effect of adenosine or the A3RAg, IB-MECA on growth of tumor cells (Nb2-11C Lymphoma, Fig. 7A) or bone marrow cells (Fig. 7B was tested). The results in Fig. 7A and 7B are shown in terms of percent inhibition and percent stimulation respectively, as compared to control (control = 0%).
- Fig. 8 is a bar graph showing the results of an in vivo experiment where the count of peripheral white blood cells (WBC) after 5 and 9 days of treatment with a chemotherapeutic drug (cyclophosphamide) was tested. The cyclophosphamide was either administered alone (gray columns) or in combination with IB-MECA administered orally (in a 1 ml solution) by daily administration, beginning 24 hours after the chemotherapeutic drug. PBS-treated mice served as control. The WBC count (WBC Counts) is given as percent over control (control = 0%).
- Fig. 9 is a bar graph showing results of an in vivo experiment in which the number of melanoma foci developed in mice following inoculation of 2x105 melanoma cells into the mice, treated with chemotherapy cyclophosphamide (CHEMO), with IB-MECA, an A3RAg with a combination of IB-MECA and CHEMO or with phosphate buffer saline (PBS) which served as control.
- Figs. 10A and 10B are bar graphs showing the results of in vivo experiment demonstrating the chemotherapeutic activity of IB-MECA. The level of white blood cells (WBC, Fig. 10A) and neutrophils (Fig. 10B) as a function of time (hours after administration) of the chemotherapeutic drug cyclophosphamide (CHEMO) with (CHEMO + IB-MECA) and without IB-MECA administration is shown). Tumor bearing mice treated with PBS served as control. The neutrophil count is shown as % over control (control = 0%).
- Fig. 11 shows weight of nude mice at 7, 10 and 14 days after onset of treatment (administration of 5-FU, Cl-IB-MECA or a combination of 5-FU and Cl-IB-MECA), as % of control (non-treated mice = 100%). The treatments consisted of administration of 5-FU (dark columns), administration of 5-FU in combination with Cl-IB-MECA (an A3RAg) - gray columns) and Cl-IB-MECA alone (white columns).
- Fig. 12A and 12B show results of an experiment in which the effect of Cl-IB-MECA in reduction of doxorubicin-induced myelotoxicity was examined. The experiment was performed in ICR mice. Fig. 12A shows the white blood cell (WBC) count while Fig. 12B shows the count of bone marrow nucleated cells. In Fig. 12A results are shown for the two different treatments at four different time periods, with the control level being indicated by a dashed line, while in Fig. 12B, the results at two different time periods are shown with the control level being represented by a bar at the left hand side.
- Fig. 13 shows the effect of anti-G-CSF antibodies on the number of white blood cells (WBC) in control mice, mice treated with a chemotheapeutic drug and mice treated with a chemotherapeutic drug and with CI-IB-MECA, administered orally (6 µg/lcg body weight, in 0.2 ml PBS). The number of WBC following injection of anti-G-CSF antibodies is represented by the light-colored columns. All results are presented as percent of control (control = 100%).
- Fig. 14 shows the size of tumor, over time, developed in nude mice following injection of HCT-116 human colon carcinoma cells, in a control group and in a treated group (oral administration of Cl-IB-MECA).
- Fig. 15 shows results of experiments similar to that of Fig. 14, where the size of the tumor developed in nude mice following injection of HCT-116 human colon carcinoma cells was measured. Four groups were tested: a control group, a group receiving the chemotherapeutic drug 5-FU, a group administered orally with Cl-IB-MECA and a group receiving a combined treatemnt of 5-FU and Cl-IB-MECA.
- Fig. 16 is a bar graph showing the tumor size at
day 30 in the experiment depicted in Fig. 15. - Fig. 17 is a bar graph showing results of an experiment where the Cl-IB-MECA-induced proliferation of bone marrow cells was measured under different concentrations (0.05 µg/ml and 0.5 µg/ml) of anti-G-CSF antibodies (0 - no antibodies). The proliferation was determined by [3H]-thymidine incorporation assay.
- Fig. 18 shows results of an in vitro experiment where proliferation of either B-16 melanoma or bone marrow cells was measured. The proliferation measured was the [3H]-thymidine incorporation assay. The cells were exposed to either 0.01 µM and 0.1 µM Cl-IB-MECA with (white columns) or without (dark columns) the A3RAg, MRS-1523. The results are shown in terms of percent of control (control = 100%).
- Figs. 19A and 19B show results of an experiment similar to that shown in Figs. 10A and 10B, respectively, performed with Cl-IB-MECA.
- Fig. 20 shows results of an in vitro experiment in which the proliferation of bone marrow cells induced by IB-MECA or Cl-IB-MECA was measured. These two A3 RAg were added to the culture of the bone marrow cells at a concentration of either 1 nM or 10 nM. with (gray columns - "(+) antagonists") or without (dark columns - "(-) antagonists"). An A3RAn, MRS-1523, at a concentration of 10 nM. The proliferation was determined by the [3H]-thymidine incorporation assay. The results are given as percent stimulation versus control (untreated bone marrow cells, control = 0%).
- Murine tumor cell lines (B-16 melanoma and Nb2 11c rat Lymphoma) were used. B-16 melanoma cells were obtained from the American Type Tissue Culture Collection (ATCC), Rockville, Maryland. Nb2-11C rat lymphoma cells [Pines M., and Gertler A. J. of Cellular Biochem., 37:119-129 (1988)] was kindly provided by Dr. A. Gertler, Hebrew university, Israel.
- Colon carcinoma cells (HCT-116) were also employed and were obtained at the ATCC.
- The cells were routinely maintained in RPMI medium containing 10% fetal bovine serum (FBS, Biological Industries, Beit Haemek, Israel). Twice a week the cells were transferred to a freshly prepared medium.
- Bone marrow cells derived from the femur of C57BL/6J mice were used. The cells were prepared as previously described [17].
- The drugs employed were: adenosine; adenosine A1 receptor agonists: CCPA [2-chloro-N6-cyclopentyl-adenosine], CPA (N-cyclopentyladenosine); A1RAn: DPCPX (1,3-dipropyl-8-cyclopentylxanthine); adenosine A2 receptor agonist: DMPA (N6-[2-(3,5-dimethoxyphenyl)-2-(2-methylphenyl)-ethyl] adenosine) A2RAn: DMPX (3,7-dimethyl-1-propargyl-xantane); A3RAg: IB-MECA (1-deoxy-1-{6-[({3-iodophenyl}methyl)amino]-9H-purine-9-yl}-N-methyl-β-D-ribofuranuronamide)), CE-IB-MECA (2-chloro-N6-3-iodobenzyl)-adenosine-5'-N-methyl-uronamide; and adenosine A3 receptor antagonist: MRS-1523 (5-propyl-2-ethyl-4-propyl-3-ethylsulfanylcarbonyl)-6-phenylpyridine-5-carboxylate) and MRS-1200 (9-chloro-2-(2-furanyl)-5-[(phenylacetyl)amino] [1,2,4,] -triazolo[1,5-c] quinazoline).
- Anti-murine G-CSF antibodies (rabbit antiserum purified by protein A chromatography, Cytolab LTD, Weizmann Institute of Science, Israel) were used.
- Cyclophosphamide was purchased from Taro Pharmaceutical Industries Ltd. Haifa Bay, Israel.
- Female ICR, C57BL/6J or mice (BALB/C origin) mice aged 3 months, weighing an average of 25 gr were used. The mice were purchased from Harlan Laboratories, Jerusalem, ISRAEL. Standarized pelleted diet and tap water were supplied.
- To test the assumption that adenosine exerts its biological effect through stimulation of G-CSF production, normal cells were cultured in the presence adenosine or an adenosine agonist or antagonist.
- For this purpose, bone marrow cells obtained from the femur of C57BL/6J or ICR mice were first disaggregated by passing through a 25G needle. Then, the cells (3x105 cells/well, in 96 microtiter plates) were incubated with RPMI medium containing 10% fetal bovine serum (FBS) in the presence of adenosine (25µM). Adenosine or agonists to the A1 and A3 adenosine receptors - CPA (an A1RAg, 0.01µM), CCPA (an A1RAg, 0.01µM), or IB-MECA (an A3RAg, 0.01µM), were added to the bone marrow cultures in the absence of adenosine; an A1 adenosine receptor antagonist, DPCPX (0.1µM), was added to a bone marrow culture in the presence of adenosine (25µM).
- Cultures containing cells suspended in RPMI medium and 5% FBS served as the control for the above detailed experiment.
- [3H]-Thymidine incorporation assay was used to evaluate the proliferation of the hone marrow cells. For this purpose, after 30 hours of incubation, each well was pulsed with 1µCi [3H]-Thymidine. After a total of 48 hours of incubation, the cells were harvested and the [3H]-Thymidine uptake was determined in an LKB liquid scintillation counter (LKB, Piscataway, NJ, USA). The results of this assay are depicted in Fig. 1 which shows that A1RAg or A3RAg have an effect on the production of G-CSF, that is similar to that obtained with adenosine.
- To confirm that adenosine and its agonists exert their effect via stimulation of G-CSF production, a further assay was conducted where anti-G-CSF antibodies (62.5ng/ml) were added to a culture of bone marrow cells in the presence of adenosine (25µM), CPA (0.01µM) or IB-MECA (0.01µM). Cell proliferation was evaluated as described above. The results of this experiment are depicted in Fig. 2 which shows that antibodies to G-CSF inhibited the stimulatory effect of adenosine and its agonists on the proliferation of bone marrow cells. These results suggest that at least some of the activities associated with interaction with adenosine receptors is mediated through the induction of G-CSF.
- The cumulative effect on the proliferation of bone marrow cells, when using a combination of an A1RAgm1 A3RAg, (CPA and IB-MECA) was evaluated. The assay was carried out similarly to that of the experiment the results of which are shown in Fig. 1. Cells, after being disaggregated, were incubated in the presence of either adenosine (25µM), CPA (0.01µM), IB-MECA (0.01µM) or a combination of IB-MECA and CPA (each in a concentration of 0.01µM) and further treated as described above. The results are depicted in Fig. 3A which shows increased combined effect of IB-MECA and CPA
- In order to compare the effect of adenosine receptor antagonist on the proliferation of bone marrow cells, following the same methodology described above cells were incubated with adenosine alone or in combination with either DMPX (an A2RAn), DPCPX (an A1RAn), MRS-1220 (an A3RAn) or with a combination of DPCPX and MRS-1220. The results are shown in Fig. 3B. As can be seen blocking the A2 receptor by DN1PX also resulted in an increased proliferation of bone marrow cells which even exceeded that of adenosine alone. In comparison, proliferation with DPCPX or MRS-1220, reduced the increase by about 50% as compared to adenosine alone, while DPCPX in combination with MRS-1220 inhibited proliferation altogether.
- Cells pre-treated as described above, were incubated at different concentrations of IB-MECA (1µM, 0.1 µM or 0.01 µM). The percent of stimulation was determined by [3H]-Thymidine incorporation assay and the results are depicted in Fig. 3 which show that IB-MECA stimulates proliferation of bone marrow in a dose dependent manner.
- Nb2-11C rat lymphoma cells (1.2x104 cells/ml) were incubated for 48 hours in 96 well microtiter plates with 1 ml RPMI medium containing 5% fetal bovine serum. Either 25µM adenosine, 0.01 µM of an adenosine receptor agonists (CPA, an A1RAg; DPMA, an A2RAg or IB-MECA, an A3RAg) or 0.1 µM of an adenosine receptor antagonists (DPCPX, an A1RAn; DMPX, an A2RAn; or MRS-1220, an A3RAn) in combination with adenosine (25µM) was added.
- Cultures containing cells suspended in RPMI medium with 5% FBS served as controls for the above detailed experiment. Extent of cell proliferation was measured by a cell count assay.
- The results are shown in Figs. 5A and 5B, comparable to the inhibition with adenosine. As can be seen, the proliferation of Nb2-11C cells, was markedly inhibited following incubation with IB-MECA, an A3RAg. No growth inhibition was seen in the presence of CPA, an A1RAg, and a lower growth inhibition was seen in the presence of DPMA, an A2RAn. The failure of CPA to inhibit the proliferation of these two tumor cells, suggested that the adenosine A1 receptor is not involved in this activity. However, the inhibitory activity of both DMPA and 1B-MECA, suggests the role of the A2 and the A3 adenosine receptors, respectively, in this inhibitory effect.
- Further, it can be seen that DPCPX, an A1RAn, had essentially no effect, while in the presence of MRS-1220, an A3RAn, the effect of adenosine on the proliferation of Nb2-11C cells was substantially abolished. A minor, however still significant effect was exerted by DMPX, an A2RAn. These findings lead to the conclusion that tumor cell growth may be effectively inhibited by an A3RAg or an A2RAn.
- In the same manner as described above, inhibition of growth of B-16 melanoma, HCT-116 colon carcinoma and Nb2-11C lymphoma, by the A3RAg, IB-MECA. was evaluated. The results are shown in Fig. 6 in terms of percent of inhibition or proliferation.
- The effect of adenosine, A3RAns and A3RAgs, on the growth of tumor cells was examined, following the experimental procedure described above.
- Briefly, Nb2-11C lymphoma or bone marrow cells were incubated in the presence of either adenosine, or IB-MECA. The dual effect of A3RAg is inhibiting the growth of tumor cells while stimulating the proliferation of bone marrow cells is depicted Figs. 7A and 7B.
- 40 C57BL6/J mice were divided into 4 groups each of which were treated, by one of the following protocols:
- 1. Control group: daily intraperitoneal (i.p.) injection of I ml saline per mouse from day of tumor inoculation until the mice were sacrificed;
- 2. Chemotherapy group: one i.p. injection of cyclophsphoamide 24 hours after inoculation of tumor cells and daily i.p. injection of 1 ml saline per mouse from day of tumor inoculation until the mice were sacrificed.
- 3. Adenosine A3 receptor agonist (A3RAg) group: daily oral administration of IB-MECA from day of tumor inoculation until the mice were sacrificed.
- 4. A3RAg + chemotherapy group: one i.p. injection of cyclophsphoamide 24 hours after inoculation of tumor cells and daily oral administration of 3 µg/kg body weight of IB-MECA.
- On
day 5 andday 9 the mice were bled from the tail vain and blood samples were obtained for white blood cell (WBC) count. The results are depicted in Fig. 8. - In addition, following 18 days the mice were sacrificed and melanoma tumor foci were counted in the lung. The results are depicted in Fig. 9.
- A further experiment was conducted in order to evaluate the chemoprotective effect of A3RAg. Mice were treated with cyclophosphoamide (50 mg/kg body weight in 0.3 ml PBS). After 48 and 72 hours from administration of the cytotoxic drug, the mice were injected i.p. with adenosine (25µg/kg body weight) or with IB-MECA (3 or 6 µg/kg body weight in 0.2 ml PBS) The number of white blood cells (WBC) and neutrophils was tested. The results are shown in Figs. 10A (WBCs) and 10B (neutrophils), respectively.
- As can be seen mice treated with cyclophosphoamide only exhibited a decline in the number of peripheral blood leukocytes and neutrophils as compared to the group treated only with IB-MECA. When adenosine or IB-MECA were administered, the total white blood cell count was restored with the latter having a very pronounced effect, yielding a complete recovery after 168 hours (7 days).
- 4 groups of nude mice (BALB/C origin), 10 in each group were treated as follows:
- Group 1:
- The mice were untreated [please confirm].
- Group 2:
- The mice were injected intraperitoneally (i.p.) with 5-fluoro-uracyl (5-FU, 30 mg/kg body weight in PBS) for five consecutive days.
- Group 3:
- The mice were injected i.p. with 5-FU as in
Group 2 but starting onday 2, and every second day thereafter, the mice were given an oral administration of CL-IB-MECA (6 µg/kg body weight, in 0.2 ml PBS. - Group 4:
- The mice received Cl-IB-MECA, as above.
- The mice weight was measured at
day - As can be seen, 5-FU had a profound effect on the weight of the mice as compared to control, while Cl-IB-MECA administered together with the 5-FU, prevented some of this weight loss. The Cl-IB-MECA by itself did essentially not give rise to any weight loss.
- This experiment demonstrates that the A3 adenosine receptor agonists have general protecting effect on some of the toxic effects of chemotherapy.
- ICR mice were treated with doxorubicin (injection of 10 mg/kg i.p. in 0.5 ml PBS). After 24, 48 and 72 hours from administration of the cytotoxic drug, the mice were orally administered with C1-IB-MECA (6 µg/kg body weight). At 72 hours. 96 hours. 120 hours and 144 hours, the mice were sacrificed and blood samples were withdrawn. In addition, bone marrow cells were aspirated from the femur of the mice and a cell count of nucleated cells from this aspirated preparation was made, following staining of the preparation with Coumassile Blue.
- Three groups of mice were tested:
- Group 1:
- (control) mice administered with PBS only.
- Group 2:
- Mice treated with doxorubicin only.
- Group 3:
- Administration of doxorubicin as above coupled with administration of CI-IB-MECA).
- The results of the white blood cell count can be seen in Fig. 12A, and that of the bone marrow nucleated cell count in Fig. 12B. These results clearly show that upon administration of Cl-IB-MECA, there is a marked increase in the number of peripheral white blood cells as well as in the number of bone marrow nucleated cells. This is evident to the protecting effect of the A3RAg against mylotoxic effects of doxorubicin.
- ICR mice, were divided into six groups as follows:
- Group 1:
- Control - administration of the vehicle only.
- Group 2:
- Control with anti-G-CSF antibodies (5 µg/mouse).
- Group 3:
- Chemotherapy - administration of cyclophosphoamide CYP - 50 mg/kg body weight).
- Group 4:
- Chemotherapy (50 mg/kg body weight CYP) + anti-G-CSF antibodies (5 µg/mouse).
- Group 5:
- Chemotherapy (50 mg/kg body weight CYP) + Cl-IB-MECA (6 µg/kg body weight) + anti-G-CSF antibodies (5 µg/mouse).
- Group 6:
- Chemotherapy (50 mg/kg body weight CYP) + Cl-IB-MECA (6 µg/kg body weight) + anti-G-CSF antibodies (5 µg/mouse).
- Each group consisted of 10 mice and the experiment was repeated twice.
- The CYP was injected intraperitoneally in 0.2 ml of PBS which served as the carrier.
- Cl-IB-MECA was given orally (in 0.2 ml PBS) at 48 hours and 72 hours following the administration of the cyclophophoamide.
- Anti-G-CSF antibodies were intravenously injected (in 0.2 ml PBS) 72 hours following the administration of the chemotherapeutic drugs.
- Blood samples were withdrawn 124 hours following chemotherapy. White blood cells (WBC) counts were made in a Coulter counter and differential cell counts were carried on smear preparations stained with May-Grundvald-Giemsa solution.
- The results of the WBC count is shown in Fig. 13. As can be seen, mice treated with cyclophosphoamide only showed a decline in the number of peripheral blood WBC. In the group that was treated with Cl-IB-MECA, the WBC counts and the percentage of neutrophils were significantly higher in comparison to the chemotheapeutic treated group (results regarding transfer of neutrophils not shown). When anti-G-CSF antibodies were administered to the control or the chemotherapy groups, an expected decline in the number of WBC was observed. Administration of anti-G-CSF antibodies to the mice treated with the combination of the chemotherapeutic drug and CI-IB-MECA, cancelled the protective effect of Cl-IB-MECA, as can clearly be seen in Fig. 13. These results lead to the conclusion that the protective effect of Cl-IB-MECA on the myeleoid system is mediated through the ability of a CI-IB-MECA to promote the production and secretion of G-CSF.
- Tumors were established by subcutaneous injection of 1x106 HCT-116 human colon cancer cells to nude mice (BALB/C origin) (Harlan, Jerusalem, Israel). Mice were treated orally with 6 µg/kg body weight CI-IB-MECA (in 0.2 ml of PBS) every other day. Mice that were treated with the vehicle only (PBS). Each group consisted of 10 mice. Tumor growth rate was determined by measuring two orthogonal diameters of each tumor twice a week, and the tumor size was estimated according to the following formula: π/6[D1D2]. The results are depicted in Fig. 14. As can be seen, in the treated group there is a marked inhibition of tumor growth.
- In a separate set of experiments a combined therapy of CI-IB-MECA and 5-fluorouracyl (5-FU) was tested. 1×106 HCT-116 cells were injected subcutaneously to nude mice. One day later, 5-FU (30 mg/kg body weight, in 0.2 ml PBS) was intraperitoneally injected and subsequently in 4 additional consecutive days. Every other day, the mice were administered orally with 5 µg/kg body weight of C1-IB-MECA (in 0.2 ml of PBS). Mice that were treated either with the vehicle only (PBS) or with 5-FU served as control. Each group consisted of 10 mice. Tumor growth rate was determined by measuring two orthogonal diameters of each tumor twice a week, and the tumor size was estimated according to the following formula: π/6[D1D2].
- The results are depicted in Fig. 15 and 16. A marked inhibition of tumor growth was observed in the groups treated with 5-FU, Cl-IB-MECA and the combined therapy of Cl-IB-MECA and 5-FU. After 20 days a clear synergistic effect between Cl-IB-MECA and 5-FU in noting the tumor mass was seen, as depicted particularly in Fig. 16 (the results represented in Fig. 16 are those at day 30).
- Bone marrow cells (3x106 celll/ml) were incubated in wells of 96 microtiter plates. Cl-IB-MECA at a final concentration of 10 nM was added with or without anti-G-CSF antibodies, at a final concentration of 0.05 and 0.5 µg/ml. Cell proliferation was measured by [3H]-thymidine incorporation assay. The results are shown in Fig. 17.
- As can be seen, the anti-G-CSF antibodies inhibit the proliferation of the bone marrow cells in a dose-dependent manner. This experiment also shows that the action of Cl-IB-MECA is mediated through the G-CSF pathway (involving G-CSF secretion from the cells).
- B-16 melanoma cells (5x105 cells/ml) and bone marrow cells (
3x 106 cells/ml) were incubated in wells of 96 microtiter plate. The culture consisted of RPMI medium supplemented with 10% FTS: C1-IB-MECA, at the concentration of 0.01 µM or 0.1 µM was added, with or without an antagonist of the adenosine A3 receptor, MRS-1523. Cell proliferation was measured by the [3H]-thymidine incorporation assay mentioned before. The results are shown in Fig. 18. As can be seen, in the presence of MRS-1523, the proliferation of both the B-16 melanoma cells and the bone marrow cells was unchanged versus control. Against this, the Cl-IB-MECA exerted an inhibitory effect on proliferation of the B-16 melanoma cells, and a proliferation stimulation effect on the bone marrow cells. - These results demonstrate the dual effect of the A3 adenosine receptor agonists.
- An example similar to that of Example 4, was performed with Cl-IB-MECA and the results are shown in Figs. 19A and 19B demonstrating the chemoprotective activity of Cl-IB-MECA.
- Murine bone marrow cells were cultured as described above. IB-MECA or Cl-IB-MECA were added to the cultures at a concentration of 1 or 10 nM, in the presence or absence of the A3RAn, MRS-1523. The antagonist was added at a concentration of 10 nM. The results are shown in Fig. 20.
- As can be seen in Fig. 20, the effect of both IB-MECA and Cl-IB-MECA is dose dependent. Furthermore, as can also be seen, this effect is inhibited to a large extent by the A3RAn.
when R4 is, a group selected from alkyl, substituted alkyl, or aryl-NH-C(Z)-, then. R5 is selected from the group consisting of substituted or unsubstituted heteroaryl-NRa-C(Z)-, heteroaryl-C(Z)-, alkaryl-NRa-C(Z)-, alkaryl-C(Z)-, aryl-NR-C(Z)- and aryl-C(Z)-;
wherein Z having the above defined meanings.
Claims (31)
- Use of an effective amount of an active ingredient for the preparation of a pharmaceutical composition for countering drug-induced myelotoxicity, wherein said active ingredient is an adenosine A3 receptor agonist (A3RAg), which exerts its prime effect through the A3 receptor and has the following general formula (I):- Y is oxygen, sulfur or CH2;- X1 is H, C1-C10 alkyl, R3RbNC(=O)- or HORc-, wherein Ra and Rb may be the same or different and are selected from the group consisting of hydrogen, C1-C10 alkyl, amino, C1-C10 haloalkyl, C1-C10 aminoalkyl, C1-C10 BOC-aminoalkyl, and C3-C10 cycloalkyl or are joined together to form a heterocyclic ring containing two to five carbon atoms, and Rc is selected from the group consisting of C1-C10 alkyl, -NH-, C1-C10 haloalkyl, C1-C10 aminoalkyl, C1-C10 Boc-aminoalkyl and C3-C10 cycloalkyl;- X2 is H, hydroxyl, C1-C10 alkylamino, C1-C10 alkylamido or C1-C10 hydroxyalkyl;- X3 and X4 each independently are hydrogen, hydroxyl, amino, amido, azido, halo, alkyl, alkoxy, carboxy, nitrilo, nitro, trifluoro, aryl, alkaryl, thio, thioester, thioether, -OCOPH, -OC(=S)OPh or both X3 and X4 are oxygen connected to >C=S to form a 5-membered ring, or X2 and X3 form the ring of formula (III):where R' and R" are independently C1-C10 alkyl;- R2 is selected from the group consisting of hydrogen, halo, C1-C10 alkylether, amino, hydrazido, C1-C10 alkylamino, C1-C10 alkoxy, C1-C10 thioalkoxy, pyridylthio, C2-C10 alkenyl; C2-C10 alkynyl, thio, and C1-C10 alkylthio; and- R3 is a -NR4R5 group with R4 being hydrogen or a group selected from alkyl, substituted alkyl or aryl-NH-C(Z)-, with Z being O, S, or NRa with Ra having the above meanings,- and R5, where R4 is hydrogen, is selected from the group consisting of Rand S-1-phenylethyl, benzyl, phenylethyl or anilide groups unsubstituted or substituted in one or more positions with a substituent selected from the group consisting of C1-C10 alkyl, amino, halo, C1-C10 haloalkyl, nitro, hydroxyl, acetoamido, C1-C10 alkoxy, and sulfonic acid or a salt thereof; or R5 is benzodioxanemethyl, furfuryl, L-propylalanyl-aminobenzyl, β-alanylamino-benzyl, T-BOC-β-alanylaminobenzyl, phenylamino, carbamoyl, phenoxy or C1-C10 cycloalkyl; or R5 is a group of the following formula:- or a suitable salt of the compound defined above, e.g. a triethylammonium salt thereof; or- when R4 is a group selected from alkyl, substituted alkyl, or aryl-NH-C(Z)-, then, R5 is selected from the group consisting of substituted or unsubstituted heteroaryl-NRa-C(Z)-, heteroaryl-C(Z)-, alkaryl-NR8-C(Z)-, alkaryl-C(Z)-, aryl-NR-C(Z)- and aryl-C(Z)-;wherein Z has the above defined meanings.
- Use according to Claim 1 for the preparation of a pharmaceutical preparation for oral administration.
- Use according to Claim 3, wherein said active ingredient is an N6-benzyladenosine-5'-uronamide derivative.
- Use according to Claim 4, wherein said active ingredient is selected from N6-2-(4-aminophenyl)ethyladenosine (APNEA), N6-(4-amino 3- iodobenzyl) adenosine-5'-(N-methyluronamide) (AB-MECA), N6-(3-iodobenzyl)-adenosine-5'-N-methyl-uronamide (IB-MECA) and 2-chloro-N6-(3-iodobenzyl)-adenosine- 5'-N-methyl-uronamide (Cl-IB-MECA).
- Use according to Claim 1, wherein the active ingredient is N6-benzyl- adenosine-5'-alkyluronamide-N1-oxide or N6-benzyladenosine-5'-N-dialkyl-uron-amide-N1 oxide.
- Use according to Claim 1, wherein the active ingredient is a xanthine-7-riboside derivative of the following general formula (V):-- X is O or S;- R6 is RaRbNC(=O)- or HORc-, wherein- Ra and Rb may be the same or different and are selected from the group consisting of hydrogen, C1-C10 alkyl, amino, C1-C10 haloalkyl, C1-C10 aminoalkyl, and C3-C10 cycloalkyl, or are joined together to form a heterocyclic ring containing two to five carbon atoms; and- Rc is selected from C1-C10 alkyl, -NH-, C1-C10 haloalkyl, C1-C10 aminoalkyl, C1-C10 Boc-aminoalkyl and C3-C10 cycloalkyl;- R7 and R8 may be the same or different and are selected from the group consisting of C1-C10 alkyl, C3-C10 cycloalkyl, R- or S-1-phenylethyl, an unsubstituted benzyl or anilide group, and a phenylether of benzyl group substituted in one or more positions with a substituent selected from the group consisting of C1-C10 alkyl, amino, halo, C1-C10 haloalkyl, nitro, hydroxyl, acetamido, C1-C10 alkoxy, and sulfonic acid;- R9 is selected from the group consisting of halo, benzyl, phenyl, C3-C10 cycloalkyl, and C1-C10 alkoxy;or a salt of such a compound, for example, a triethylammonium salt thereof.
- Use according to Claim 1, wherein said drug is a chemotherapeutic drug given to the subject within the framework of anti-cancer treatment.
- Use of an effective amount of an active ingredient for the preparation of a pharmaceutical composition for inducing proliferation or differentiation of bone marrow or white blood cells, wherein the active ingredient is an adenosine A3 receptor agonist (A3RAg), which exerts its prime effect through the A3 receptor and is that defined in any one of claims 1-7.
- Use according to Claim 9, for the preparation of a pharmaceutical composition for oral administration.
- Use of an effective amount of an active ingredient for the preparation of a pharmaceutical composition for the prevention or treatment of leukopenia, the active ingredient being an adenosine A3 receptor agonist (A3RAg), which exerts its prime effect through the A3 receptor and is that defined in any one of claims 1 - 7.
- Use according to Claim 11, for the preparation of a pharmaceutical composition for the prevention or treatment of drug- induced leukopenia.
- Use of an effective amount of an active ingredient for the preparation of a pharmaceutical composition for the prevention or treatment of toxic side effects of a drug, the active ingredient being an adenosine A3 receptor agonist (A3RAg), which exerts its prime effect through the A3 receptor and is that defined in any one of claims 1-7.
- Use according to Claim 13, wherein the toxic side effect is manifested by weight loss.
- Use according to any one of Claims 12-14, wherein said drug is a chemotherapeutic drug.
- Use according to Claim 13, for the preparation of a pharmaceutical composition for elevating the level of circulating leukocytes in a subject.
- Use according to any one of Claims 13-16, for the preparation of a pharmaceutical composition for oral administration.
- Use of an effective amount of an active ingredient being an adenosine A3 receptor agonist (A3RAg), which exerts its prime effect through the A3 receptor, for the manufacture of a pharmaceutical composition, wherein said manufacture comprises mixing said active ingredient with a drug that can cause a toxic side effect in a treated subject.
- Use according to Claim 18, wherein said drug is a chemotherapeutic drug.
- Use according to Claim 18 or 19 for the preparation of a pharmaceutical composition for oral administration.
- Use of an effective amount of an active ingredient for the preparation of a pharmaceutical composition for selectively inhibiting abnormal cell growth, the active ingredient being an adenosine A3 receptor agonist (A3RAg), which exerts its prime effect through the A3 receptor and is that defined in any one of claims 1 - 7.
- Use according to Claim 21, wherein said abnormal cell growth is growth or proliferation of tumor cells.
- Use according to Claim 21, wherein said abnormal cell growth is associated with an autoimmune disease.
- Use according to any of Claims 21-23, for the preparation of a pharmaceutical composition for oral administration.
- Use according to any of Claims 21-24, wherein said pharmaceutical composition is intended for administration in combination with a chemotherapeutic drug.
- Use of an effective amount of an A3RAg, which exerts its prime effect through the A3 receptor, for the preparation of a pharmaceutical composition for the treatment of cancer in a subject, the pharmaceutical composition yielding a dual effect in both inhibiting proliferation of cancer cells and countering toxic side effects of a chemotherapeutic drug treatment of the same subject, wherein the active ingredient is that defined in any one of claims 1 - 7.
- Use according to Claim 26, wherein the active ingredient synergizes with said drug to yield a stronger anti-tumor effect.
- Use according to Claim 26 or 27, wherein the active ingredient is formulated for oral administration.
- Use according to any of Claims 1-28, wherein the dosage of the A3RAg is < 100 µg/kg body weight.
- Use according to Claim 29, wherein the dosage is < 50 µg/kg body weight.
- Use according to Claim 30, wherein the dosage is within the range of 1-10 µg/kg body weight.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL13186499 | 1999-09-10 | ||
IL13186499A IL131864A0 (en) | 1999-09-10 | 1999-09-10 | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist |
IL13368099A IL133680A0 (en) | 1999-09-10 | 1999-12-23 | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist |
IL13368099 | 1999-12-23 | ||
PCT/IL2000/000550 WO2001019360A2 (en) | 1999-09-10 | 2000-09-08 | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1261322A2 EP1261322A2 (en) | 2002-12-04 |
EP1261322B1 true EP1261322B1 (en) | 2007-11-28 |
Family
ID=26323880
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP00956773A Expired - Lifetime EP1261322B1 (en) | 1999-09-10 | 2000-09-08 | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist |
Country Status (19)
Country | Link |
---|---|
US (2) | US7064112B1 (en) |
EP (1) | EP1261322B1 (en) |
JP (2) | JP4980530B2 (en) |
KR (2) | KR100584797B1 (en) |
CN (1) | CN100358512C (en) |
AU (1) | AU782826B2 (en) |
BR (1) | BR0013905A (en) |
CA (1) | CA2384111C (en) |
DE (1) | DE60037277T2 (en) |
DK (1) | DK1261322T3 (en) |
ES (1) | ES2296637T3 (en) |
HK (1) | HK1052653B (en) |
HU (1) | HU226913B1 (en) |
IL (1) | IL133680A0 (en) |
MX (1) | MXPA02002546A (en) |
PL (1) | PL199852B1 (en) |
PT (1) | PT1261322E (en) |
RU (1) | RU2239455C2 (en) |
WO (1) | WO2001019360A2 (en) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL121272A (en) * | 1997-07-10 | 2000-06-01 | Can Fite Technologies Ltd | Pharmaceutical compositions comprising adenosine and their use for treating or preventing leukopenia |
ATE385794T1 (en) | 2000-06-21 | 2008-03-15 | Hoffmann La Roche | BENZOTHIAZOLE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S AND PARKINSON'S |
US7589075B2 (en) | 2001-01-16 | 2009-09-15 | Can-Fite Biopharma Ltd. | Use of an adenosine A3 receptor agonist for inhibition of viral replication |
US20020115635A1 (en) * | 2001-02-21 | 2002-08-22 | Pnina Fishman | Modulation of GSK-3beta activity and its different uses |
US20040204481A1 (en) * | 2001-04-12 | 2004-10-14 | Pnina Fishman | Activation of natural killer cells by adenosine A3 receptor agonists |
US7049303B2 (en) | 2001-11-07 | 2006-05-23 | Medical Research Council | Inhibition of viruses |
US7414036B2 (en) | 2002-01-25 | 2008-08-19 | Muscagen Limited | Compounds useful as A3 adenosine receptor agonists |
WO2004038419A1 (en) * | 2002-10-22 | 2004-05-06 | Can-Fite Biopharma Ltd. | The use of the a3 adenosine receptor as a marker for a diseased state |
US7087761B2 (en) | 2003-01-07 | 2006-08-08 | Hoffmann-La Roche Inc. | Cyclization process for substituted benzothiazole derivatives |
CA2567703C (en) | 2004-05-24 | 2013-03-05 | F. Hoffmann-La Roche Ag | 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide |
PL1758596T3 (en) | 2004-05-26 | 2011-01-31 | Inotek Pharmaceuticals Corp | Purine derivatives as adenosine a1 receptor agonists and methods of use thereof |
US7825102B2 (en) | 2004-07-28 | 2010-11-02 | Can-Fite Biopharma Ltd. | Treatment of dry eye conditions |
BRPI0515506A (en) | 2004-09-20 | 2008-07-29 | Inotek Pharmaceuticals Corp | purine derivatives and methods of use thereof |
ES2309814T3 (en) | 2004-11-05 | 2008-12-16 | F. Hoffmann-La Roche Ag | PROCESS FOR OBTAINING DERIVATIVES OF ISONICOTINIC ACID. |
CA2586845A1 (en) * | 2004-11-08 | 2006-05-11 | Can-Fite Biopharma Ltd. | Therapeutic treatment of accelerated bone resorption |
AU2005336924A1 (en) * | 2004-11-22 | 2007-04-12 | King Pharmaceuticals Research & Development, Inc. | Enhancing treatment of cancer and HIF-1 mediated disoders with adenosine A3 receptor antagonists |
SI1863818T1 (en) | 2005-03-23 | 2010-05-31 | Hoffmann La Roche | Acetylenyl-pyrazolo-pvrimidine derivatives as mglur2 antagonists |
BRPI0616571A2 (en) | 2005-09-27 | 2011-06-21 | Hoffmann La Roche | oxadiazolyl pyrazol pyridimines as mglur2 antagonists, process for their preparation, pharmaceutical composition containing them and use thereof |
CA2627319A1 (en) | 2005-11-30 | 2007-06-07 | Prakash Jagtap | Purine derivatives and methods of use thereof |
KR101037095B1 (en) * | 2006-01-27 | 2011-05-26 | 캔-파이트 바이오파마 리미티드 | Adenosine a3 receptor agonists for the treatment of dry eye disorders |
WO2008023362A2 (en) * | 2006-08-21 | 2008-02-28 | Can-Fite Biopharma Ltd. | Use of a combination of methotrexate and an a3ar agonist for the treatment of cancer |
CA2665616A1 (en) * | 2006-10-06 | 2008-04-17 | The Trustees Of The University Of Pennsylvania | Effective delivery of cross-species a3 adenosine-receptor antagonists toreduce intraocular pressure |
GB0625100D0 (en) * | 2006-12-15 | 2007-01-24 | Univ Murcia | Epigallocatechin-3-gallate compositions for cancer therapy and chemoprotection |
US20090088403A1 (en) * | 2007-05-07 | 2009-04-02 | Randy Blakely | A3 adenosine receptors as targets for the modulation of central serotonergic signaling |
AU2008276451A1 (en) * | 2007-07-17 | 2009-01-22 | Zalicus Inc. | Treatments of B-cell proliferative disorders |
US20090047243A1 (en) * | 2007-07-17 | 2009-02-19 | Richard Rickles | Combinations for the treatment of b-cell proliferative disorders |
WO2009151569A2 (en) * | 2008-06-09 | 2009-12-17 | Combinatorx, Incorporated | Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders |
EP2334179A4 (en) * | 2008-09-08 | 2012-09-26 | Merck Sharp & Dohme | Ahcy hydrolase inhibitors for treatment of hyper homocysteinemia |
JP5849044B2 (en) | 2009-05-17 | 2016-01-27 | キャン−ファイト バイオファーマ リミテッド | A3 adenosine receptor agonists for reducing intraocular pressure |
EP2456419B1 (en) | 2009-07-21 | 2016-11-23 | Oradin Pharmaceutical Ltd. | A3 adenosine receptor ligands for modulation of pigmentation |
WO2011074903A2 (en) * | 2009-12-17 | 2011-06-23 | 이화여자대학교 산학협력단 | Pharmaceutical composition containing a3 adenosine receptor agonist |
ME02608B (en) | 2010-01-11 | 2017-06-20 | Inotek Pharmaceuticals Corp | Combination, kit and method of reducing intraocular pressure |
US20130045943A1 (en) | 2010-03-03 | 2013-02-21 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of | A3ar agonists for the treatment of uveitis |
EP2569325A4 (en) | 2010-03-26 | 2013-10-09 | Inotek Pharmaceuticals Corp | Method of reducing intraocular pressure in humans using n6 - cyclopentyladenosine (cpa), cpa derivatives or prodrugs thereof |
US20130109645A1 (en) * | 2010-03-31 | 2013-05-02 | The united States of America,as represented by Secretary,Dept.,of Health and Human Services | Adenosine receptor agonists for the treatment and prevention of vascular or joint capsule calcification disorders |
HUE041509T2 (en) | 2011-12-22 | 2019-05-28 | Janssen Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
WO2013111132A1 (en) * | 2012-01-23 | 2013-08-01 | Can-Fite Biopharma Ltd. | Treatment of liver conditions |
SI2807178T1 (en) | 2012-01-26 | 2017-09-29 | Inotek Pharmaceuticals Corporation | Anhydrous polymorphs of (2r,3s,4r,5r)-5-(6-(cyclopentylamino)-9h-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl) ) methyl nitrate and processes of preparation thereof |
USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
US8822460B2 (en) | 2012-04-06 | 2014-09-02 | Janssen Pharmaceutica Nv | Fused cyclopentyl antagonists of CCR2 |
CA2879126A1 (en) | 2012-07-19 | 2014-01-23 | Janssen Pharmaceutica Nv | Octahydro-cyclopentapyrrolyl antagonists of ccr2 |
BR112015002697A8 (en) | 2012-08-09 | 2018-01-16 | Can Fite Biopharma Ltd | use of a3 adenosine receptor binder (a3ar), a3ar binder, and pharmaceutical composition to treat sexual dysfunction in an individual |
SG11201506882YA (en) | 2013-03-15 | 2015-09-29 | Inotek Pharmaceuticals Corp | Ophthalmic formulations |
IL242723B (en) | 2015-11-23 | 2019-12-31 | Can Fite Biopharma Ltd | An a3 adenosine receptor ligand for use in treating ectopic fat accumulation |
KR102445887B1 (en) | 2016-04-21 | 2022-09-21 | 아스트로사이트 파마슈티컬스, 인코포레이티드 | Compounds and methods for treating neurological and cardiovascular conditions |
IL254535A0 (en) | 2017-09-17 | 2017-11-30 | Can Fite Biopharma Ltd | A3 adenosine receptor ligand for managing cytokine release syndrome |
WO2019157317A1 (en) | 2018-02-09 | 2019-08-15 | Astrocyte Pharmaceuticals, Inc. | Compounds and methods for treating addiction and related disorders |
US10765693B2 (en) | 2018-09-26 | 2020-09-08 | Astrocyte Pharmaceuticals, Inc. | Polymorphic compounds and uses thereof |
IL264112A (en) | 2019-01-06 | 2020-07-30 | Fishman Pnina | An a3 adenosine receptor ligand for use for reducing level of adipocytes |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5443836A (en) * | 1993-03-15 | 1995-08-22 | Gensia, Inc. | Methods for protecting tissues and organs from ischemic damage |
DE69428536T2 (en) * | 1993-07-13 | 2002-06-06 | Nasa | A3 ADENOSINE RECEPTOR AGONISTS |
US5688774A (en) * | 1993-07-13 | 1997-11-18 | The United States Of America As Represented By The Department Of Health And Human Services | A3 adenosine receptor agonists |
GB2289218A (en) * | 1994-05-06 | 1995-11-15 | Merck & Co Inc | Inhibition of TNFalpha production with agonists of the A2b subtype of the adenosine receptor |
RU2071770C1 (en) | 1994-12-14 | 1997-01-20 | Владислав Алексеевич Шматко | Method of uterus cervix and ovary cancer treatment |
RU2071771C1 (en) | 1995-01-11 | 1997-01-20 | Владислав Алексеевич Шматко | Method of mamma cancer treatment |
EP0991414A4 (en) * | 1997-05-09 | 2002-10-02 | Univ Pennsylvania | Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists |
IL121272A (en) * | 1997-07-10 | 2000-06-01 | Can Fite Technologies Ltd | Pharmaceutical compositions comprising adenosine and their use for treating or preventing leukopenia |
US6048865A (en) | 1997-07-29 | 2000-04-11 | Medco Research, Inc. | N6 -substituted-adenosine-5'-uronamides as adenosine receptor modulator |
JP2003517423A (en) * | 1997-07-29 | 2003-05-27 | メドコ リサーチ、インコーポレイテッド | N6-substituted adenosine-5'-uronamide as adenosine receptor modulator |
AU1363699A (en) | 1997-10-23 | 1999-05-10 | National Institute Of Health | Methods for reducing ischemic injury of the heart via the sequential administ ration of monophosphoryl lipid a and adenosine receptor agents |
CA2316994A1 (en) * | 1998-06-08 | 1999-12-16 | Epigenesis Pharmaceuticals, Inc. | Composition and method for prevention and treatment of cardiopulmonary and renal failure or damage associated with ischemia, endotoxin release, ards or brought about by administration of certain drugs |
US6448253B1 (en) | 1998-09-16 | 2002-09-10 | King Pharmaceuticals Research And Development, Inc. | Adenosine A3 receptor modulators |
IL127947A0 (en) | 1999-01-07 | 1999-11-30 | Can Fite Technologies Ltd | Pharmaceutical use of adenosine agonists |
BR0007864A (en) | 1999-02-01 | 2001-11-06 | Univ Virginia | Compound, and, use of a compound |
IL131096A (en) | 1999-07-26 | 2004-09-27 | Can Fite Technologies Ltd | Method for preparing a composition derived from muscle tissue |
-
1999
- 1999-12-23 IL IL13368099A patent/IL133680A0/en not_active IP Right Cessation
-
2000
- 2000-09-08 WO PCT/IL2000/000550 patent/WO2001019360A2/en active IP Right Grant
- 2000-09-08 KR KR1020027003164A patent/KR100584797B1/en active IP Right Grant
- 2000-09-08 PT PT00956773T patent/PT1261322E/en unknown
- 2000-09-08 RU RU2002109228/15A patent/RU2239455C2/en active
- 2000-09-08 JP JP2001522994A patent/JP4980530B2/en not_active Expired - Lifetime
- 2000-09-08 MX MXPA02002546A patent/MXPA02002546A/en active IP Right Grant
- 2000-09-08 CN CNB008148007A patent/CN100358512C/en not_active Expired - Lifetime
- 2000-09-08 US US09/700,751 patent/US7064112B1/en not_active Expired - Lifetime
- 2000-09-08 PL PL356469A patent/PL199852B1/en unknown
- 2000-09-08 ES ES00956773T patent/ES2296637T3/en not_active Expired - Lifetime
- 2000-09-08 CA CA002384111A patent/CA2384111C/en not_active Expired - Lifetime
- 2000-09-08 EP EP00956773A patent/EP1261322B1/en not_active Expired - Lifetime
- 2000-09-08 DK DK00956773T patent/DK1261322T3/en active
- 2000-09-08 DE DE60037277T patent/DE60037277T2/en not_active Expired - Lifetime
- 2000-09-08 AU AU68634/00A patent/AU782826B2/en not_active Expired
- 2000-09-08 BR BR0013905-0A patent/BR0013905A/en not_active Application Discontinuation
- 2000-09-08 HU HU0203870A patent/HU226913B1/en unknown
- 2000-09-08 KR KR1020067006473A patent/KR100674529B1/en active IP Right Grant
-
2003
- 2003-07-11 HK HK03105018.4A patent/HK1052653B/en not_active IP Right Cessation
-
2005
- 2005-11-25 US US11/286,376 patent/US20060084626A1/en not_active Abandoned
-
2007
- 2007-05-14 JP JP2007128137A patent/JP2007204496A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1261322B1 (en) | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist | |
US6579857B1 (en) | Combination cancer therapy comprising adenosine and deaminase enzyme inhibitors | |
US20040106572A1 (en) | Use of an adenosine a3 receptor agonist for inhibition of viral replication | |
EP1383515B1 (en) | Activation of natural killer cells by adenosine a3 receptor agonists | |
AU2002219497A1 (en) | Use of an adenosine A3 receptor agonist for inhibition of viral replication | |
EP1272897B1 (en) | Adenosine a2a receptor antagonists for treating and preventing hepatic fibrosis, cirrhosis and fatty liver | |
AU2001238124A1 (en) | Adenosine a2a receptor antagonists for treating and preventing hepatic fibrosis,cirrhosis and fatty liver | |
US6638914B1 (en) | Pharmaceutical administration of adenosine agonists | |
US20080090848A1 (en) | Substituted Purinyl Derivatives With Immunomodulator And Chemoprotective Activity And Use Alone Or With Medium-Chain Length Fatty Acids Or Glycerides | |
KR20040078123A (en) | Combinations Comprising Epothilones and Anti-Metabolites | |
US6790839B2 (en) | Pharmaceutical administration of adenosine agonists | |
Bashey | Immunosuppression with limited toxicity: the characteristics of nucleoside analogs and anti-lymphocyte antibodies used in nonmyeloablative hematopoietic cell transplantation | |
US20020037871A1 (en) | Pharmaceutical use of adenosine agonists | |
WO2022182857A1 (en) | Use of a bet inhibitor alone or in combination with fedratinib or ruxolitinib for treating a hematological malignancy such as myelofibrosis | |
AU2006203699A1 (en) | Adenosine A2A receptor antagonists for treating and preventing hepatic fibrosis, cirrhosis and fatty liver | |
CN101164548A (en) | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20020410 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
17Q | First examination report despatched |
Effective date: 20030204 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP Ref country code: CH Ref legal event code: NV Representative=s name: BOVARD AG PATENTANWAELTE |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20071226 |
|
REF | Corresponds to: |
Ref document number: 60037277 Country of ref document: DE Date of ref document: 20080110 Kind code of ref document: P |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: EP Ref document number: 20080400289 Country of ref document: GR |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2296637 Country of ref document: ES Kind code of ref document: T3 |
|
ET | Fr: translation filed | ||
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20080829 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20080930 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20071128 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PFA Owner name: CAN-FITE BIOPHARMA LTD. Free format text: CAN-FITE BIOPHARMA LTD.#10 BAREKET STREET#49170 PETACH TIKVA (IL) -TRANSFER TO- CAN-FITE BIOPHARMA LTD.#10 BAREKET STREET#49170 PETACH TIKVA (IL) |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 17 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 18 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 19 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20190926 Year of fee payment: 20 Ref country code: IT Payment date: 20190923 Year of fee payment: 20 Ref country code: IE Payment date: 20190923 Year of fee payment: 20 Ref country code: NL Payment date: 20190926 Year of fee payment: 20 Ref country code: SE Payment date: 20190926 Year of fee payment: 20 Ref country code: FI Payment date: 20190920 Year of fee payment: 20 Ref country code: LU Payment date: 20190926 Year of fee payment: 20 Ref country code: DK Payment date: 20190924 Year of fee payment: 20 Ref country code: PT Payment date: 20190829 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GR Payment date: 20190924 Year of fee payment: 20 Ref country code: BE Payment date: 20190926 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20190930 Year of fee payment: 20 Ref country code: AT Payment date: 20190926 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20191129 Year of fee payment: 20 Ref country code: CH Payment date: 20190925 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20191021 Year of fee payment: 20 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R071 Ref document number: 60037277 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MK Effective date: 20200907 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EUP Expiry date: 20200908 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: PE20 Expiry date: 20200907 |
|
REG | Reference to a national code |
Ref country code: FI Ref legal event code: MAE |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MK Effective date: 20200908 Ref country code: AT Ref legal event code: MK07 Ref document number: 379446 Country of ref document: AT Kind code of ref document: T Effective date: 20200908 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MK9A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20200907 Ref country code: PT Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20200917 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20200908 Ref country code: ES Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20200909 |